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A B S T R A C T
Background
Biofeedback therapy has been used to treat the symptoms of people with chronic constipation referred to specialist services within sec-
ondary and tertiary care settings. However, different methods of biofeedback are used within different centres and the magnitude of sug-
gested benefits and comparable effectiveness of different methods of biofeedback has yet to be established.
Objectives
To determine the efficacy and safety of biofeedback for the treatment of chronic idiopathic (functional) constipation in adults.
Search methods
We searched the following databases from inception to 16 December 2013: CENTRAL, the Cochrane Complementary Medicine Field, the
Cochrane IBD/FBD Review Group Specialized Register, MEDLINE, EMBASE, CINAHL, British Nursing Index, and PsychINFO. Hand searching
of conference proceedings and the reference lists of relevant articles was also undertaken.
Selection criteria
All randomised trials evaluating biofeedback in adults with chronic idiopathic constipation were considered for inclusion.
Data collection and analysis
The primary outcome was global or clinical improvement as defined by the included studies. Secondary outcomes included quality of life,
and adverse events as defined by the included studies. Where possible, we calculated the risk ratio (RR) and corresponding 95% confidence
interval (CI) for dichotomous outcomes and the mean difference (MD) and 95% CI for continuous outcomes. We assessed the methodolog-
ical quality of included studies using the Cochrane risk of bias tool. The overall quality of the evidence supporting each outcome was as-
sessed using the GRADE criteria.
Main results
Seventeen eligible studies were identified with a total of 931 participants. Most participants had chronic constipation and dyssynergic
defecation. Sixteen of the trials were at high risk of bias for blinding. Attrition bias (4 trials) and other potential bias (5 trials) was also not-
ed. Due to differences between study populations, the heterogeneity of the different samples and large range of different outcome mea-
sures, meta-analysis was not possible. Different effect sizes were reported ranging from 40 to 100% of patients who received biofeedback
improving following the intervention. While electromyograph (EMG) biofeedback was the most commonly used, there is a lack of evidence
as to whether any one method of biofeedback is more effective than any other method of biofeedback. We found low or very low quality
evidence that biofeedback is superior to oral diazepam, sham biofeedback and laxatives. One study (n = 60) found EMG biofeedback to
be superior to oral diazepam. Seventy per cent (21/30) of biofeedback patients had improved constipation at three month follow-up com-
pared to 23% (7/30) of diazepam patients (RR 3.00, 95% CI 1.51 to 5.98). One study compared manometry biofeedback to sham biofeed-
back or standard therapy consisting of diet, exercise and laxatives. The mean number of complete spontaneous bowel movements (CSBM)
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per week at three months was 4.6 in the biofeedback group compared to 2.8 in the sham biofeedback group (MD 1.80, 95% CI 1.25 to 2.35;
52 patients). The mean number of CSBM per week at three months was 4.6 in the biofeedback group compared to 1.9 in the standard care
group (MD 2.70, 95% CI 1.99 to 3.41; 49 patients). Another study (n = 109) compared EMG biofeedback to conventional treatment with lax-
atives and dietary and lifestyle advice. This study found that at both 6 and 12 months 80% (43/54) of biofeedback patients reported clinical
improvement compared to 22% (12/55) laxative-treated patients (RR 3.65, 95% CI 2.17 to 6.13). Some surgical procedures (partial division
of puborectalis and stapled transanal rectal resection (STARR)) were reported to be superior to biofeedback, although with a high risk of
adverse events in the surgical groups (wound infection, faecal incontinence, pain, and bleeding that required further surgical intervention).
Successful treatment, defined as a decrease in the obstructed defecation score of > 50% at one year was reported in 33% (3/39) of EMG
biofeedback patients compared to 82% (44/54) of STARR patients (RR 0.41, 95% CI 0.26 to 0.65). For the other study the mean constipation
score at one year was 16.1 in the balloon sensory biofeedback group compared to 10.5 in the partial division of puborectalis surgery group
(MD 5.60, 95% CI 4.67 to 6.53; 40 patients). Another study (n = 60) found no significant difference in efficacy did not demonstrate the supe-
riority of a surgical intervention (posterior myomectomy of internal anal sphincter and puborectalis) over biofeedback. Conflicting results
were found regarding the comparative effectiveness of biofeedback and botulinum toxin-A. One small study (48 participants) suggested
that botulinum toxin-A injection may have short term benefits over biofeedback, but the relative effects of treatments were uncertain at
one year follow-up. No adverse events were reported for biofeedback, although this was not specifically reported in the majority of studies.
The results of all of these studies need to be interpreted with caution as GRADE analyses rated the overall quality of the evidence for the
primary outcomes (i.e. clinical or global improvement as defined by the studies) as low or very low due to high risk of bias (i.e. open label
studies, self-selection bias, incomplete outcome data, and baseline imbalance) and imprecision (i.e. sparse data).
Authors' conclusions
Currently there is insufficient evidence to allow any firm conclusions regarding the efficacy and safety of biofeedback for the management
of people with chronic constipation. We found low or very low quality evidence from single studies to support the effectiveness of biofeed-
back for the management of people with chronic constipation and dyssynergic defecation. However, the majority of trials are of poor
methodological quality and subject to bias. Further well-designed randomised controlled trials with adequate sample sizes, validated
outcome measures (especially patient reported outcome measures) and long-term follow-up are required to allow definitive conclusions
to be drawn.
P L A I N   L A N G U A G E   S U M M A R Y
Biofeedback (use of equipment to retrain the muscles around the anus and coordinated pushing) for the treatment of chronic
constipation in adults
Chronic constipation (inability to achieve satisfactory bowel emptying for a prolonged period with no apparent medical cause) can be an
embarrassing and socially restricting problem. There are many possible causes, including an inability to relax the muscles which control
bowel movements. ’Biofeedback’, where computer equipment or a rectal balloon is used to show people how to coordinate and use the
muscles properly, is often recommended.
The purpose of this systematic review was to examine the effectiveness and side effects of biofeedback therapy used for the treatment
of chronic constipation in adults who are unable to relax the muscles which control bowel movements. This review identified 17 eligible
studies that included a total of 931 participants. The studies either compared the effectiveness of different types of biofeedback to one
another, or biofeedback to a sham biofeedback (a fake biofeedback treatment) or biofeedback to standard treatment consisting of diet,
exercise and laxatives. There is some evidence that biofeedback is superior to treatment with oral diazepam (a sedative known as Vali-
um), sham biofeedback and laxatives. One study of 60 participants found biofeedback with computer equipment to be superior to oral
diazepam (a sedative drug that is not usually used to treat constipation). Another study of 77 participants suggests that biofeedback is
superior to sham biofeedback or standard therapy consisting of diet, exercise and laxatives. Another study with 109 participants also sug-
gested that biofeedback with computer equipment is superior to conventional treatment with laxatives and dietary and lifestyle advice.
Some surgical procedures (partial division of puborectalis and stapled transanal rectal resection) were reported to be superior to biofeed-
back. However, there was a high risk of side effects in the surgical treatment groups including wound infection, faecal incontinence, pain,
and bleeding that required further surgery. One other study of 60 participants did not find a difference in effectiveness between surgery
(posterior myomectomy of internal anal sphincter and puborectalis) and biofeedback treatment. Botulinum toxin-A injection may have
short term benefits over biofeedback, but the benefit does not last. No adverse events were reported for biofeedback, although this was
not specifically reported in the majority of studies. The results of this review need to be interpreted with caution as they are based on
small numbers of patients and the overall quality of the evidence from the studies was rated as low or very low due to lack of precision
of the results and the low methodological quality of the studies. Thus no firm conclusions can be made regarding the effectiveness and
potential side effects of biofeedback treatment for patients with chronic constipation who are unable to relax the muscles which control
bowel movements. Further larger trials are needed to provide better evidence.
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Summary of findings for the main comparison.   Balloon sensory training biofeedback versus surgery for chronic constipation
Balloon sensory training biofeedback versus surgery for chronic constipation
Patient or population: Patients with anismus and chronic constipation
Settings: Outpatient procedure
Intervention: Balloon sensory training biofeedback versus surgery
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Balloon sensory train-
ing biofeedback versus
surgery
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Number im-
proved at
one year
700 per
10001
301 per 1000
(147 to 623)
RR 0.43 
(0.21 to 0.89)
40
(1 study)
⊕⊝⊝⊝
very low2,3
 
Constipation
score at one
year
The mean
constipation
score in the
control group
at one year
was 10.5
The mean constipation
score in the intervention
group was 5.6 points
higher (4.67 to 6.53 high-
er)
  40
(1 study)
⊕⊝⊝⊝
very low2,4
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; MD: Mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control group risk estimate comes from the control arm of the included trial.
2 High risk of bias in the included study due to open-label design and risk of other bias
3 Very sparse data (20 events) and wide confidence intervals
4 Sparse data (40 patients)
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Summary of findings 2.   Balloon sensory training biofeedback versus botulinum toxin-A for chronic constipation
Balloon sensory training biofeedback versus botulinum toxin-A for chronic constipation
Patient or population: Patients with anismus and chronic constipation
Settings: Outpatient procedure
Intervention: Balloon sensory training biofeedback versus surgery
Illustrative comparative risks* (95%
CI)
Assumed risk Corresponding risk
Outcomes
Control Balloon sensory
training biofeedback
versus surgery
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Constipation
score at one
year
The mean
constipation
score in the
control group
at one year
was 14.3
The mean constipa-
tion score in the inter-
vention group was 1.8
points higher (0.87 to
2.73 higher)
  40
(1 study)
⊕⊝⊝⊝
very low1,2
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; MD: Mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 High risk of bias in the included study due to open-label design and risk of other bias
2 Sparse data (40 patients)
 
 
Summary of findings 3.   EMG biofeedback versus diazepam for chronic constipation
EMG biofeedback versus diazepam for chronic constipation
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Patient or population: Patients with pelvic floor dyssynergia and chronic constipation
Settings: Outpatient procedure
Intervention: EMG biofeedback versus diazepam
Illustrative comparative
risks* (95% CI)
Assumed risk Correspond-
ing risk
Outcomes
Control EMG biofeed-
back versus
diazepam
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
Number im-
proved at
three months
233 per
10001
699 per 1000
(352 to 1393)
RR 3.00 
(1.51 to 5.98)
60
(1 study)
⊕⊝⊝⊝
very low2,3
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; MD: Mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control group risk estimate comes from the control arm of the included trial.
2 High risk of bias in the included study due to open-label design and risk of self-selection bias among participants.
3 Very sparse data (28 events) and wide confidence intervals.
 
 
Summary of findings 4.   EMG biofeedback versus STARR procedure for obstructed defecation
EMG biofeedback versus STARR procedure for obstructed defecation
Patient or population: Patients with obstructed defecation
Settings: Outpatient procedure
Intervention: EMG biofeedback versus STARR procedure
Outcomes Illustrative comparative risks* (95%
CI)
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
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Assumed risk Corresponding risk
Control EMG biofeedback ver-
sus STARR
Treatment
success at
one year1
815 per
10002
334 per 1000
(212 to 530)
RR 0.41 
(0.26 to 0.65)
93
(1 study)
⊕⊕⊝⊝
low3,4
 
Obstructed
defecation
score at one
year
The mean ob-
structed defe-
cation score
in the control
group at one
year was 4.7
The mean obstruct-
ed defecation score in
the intervention group
was 5.5 points higher
(3.44 to 7.56 higher)
  93
(1 study)
⊕⊕⊝⊝
low3,5
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; MD: Mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Treatment success was defined as a decrease in the obstructed defecation score of > 50% at one year.
2 Control group risk estimate comes from the control arm of the included trial.
3 High risk of bias in the included study due to open-label design and incomplete outcome data.
4 Sparse data (57 events) and wide confidence intervals.
5 Sparse data (93 patients).
 
 
Summary of findings 5.   EMG biofeedback versus laxative for chronic constipation
EMG biofeedback versus laxative for chronic constipation
Patient or population: Patients with pelvic floor dyssynergia and chronic constipation
Settings: Outpatient procedure
Intervention: EMG biofeedback versus laxative
Outcomes Illustrative comparative
risks* (95% CI)
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evi-
dence
(GRADE)
Comments
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Assumed risk Correspond-
ing risk
Control EMG biofeed-
back versus
laxative
Major clini-
cal improve-
ment at six
months
218 per
10001
796 per 1000
(473 to 1336)
RR 3.65 
(2.17 to 6.13)
109
(1 study)
⊕⊕⊝⊝
low2,3
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; MD: Mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Control group risk estimate comes from the control arm of the included trial.
2 High risk of bias in the included study due to open-label design.
3 Sparse data (55 events) and wide confidence intervals.
 
 
Summary of findings 6.   Manometry biofeedback versus sham biofeedback for chronic constipation
Manometry biofeedback versus sham biofeedback for chronic constipation
Patient or population: Patients with pelvic floor dyssynergia and chronic constipation
Settings: Outpatient procedure
Intervention: Manometry biofeedback versus sham biofeedback
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Manometry biofeed-
back versus sham
biofeedback
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
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Complete
spontaneous
bowel move-
ments per
week at
three months
The mean num-
ber of complete
spontaneous
bowel move-
ments per week
in the sham con-
trol group at
three months
year was 2.8
The mean number of
complete spontaneous
bowel movements in the
intervention group was
1.8 movements higher
(1.25 to 2.35 higher)
  52
(1 study)
⊕⊕⊝⊝
low1,2
 
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; MD: Mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 High risk of bias in the included study due to open-label design and the two groups were not equal at baseline as the biofeedback group had a significantly lower defecation
index and relatively greater pelvic floor dysfunction than the sham group.
2 Sparse data (52 patients).
 
 
Summary of findings 7.   Manometry biofeedback versus standard care for chronic constipation
Manometry biofeedback versus standard care for chronic constipation
Patient or population: Patients with pelvic floor dyssynergia and chronic constipation
Settings: Outpatient procedure
Intervention: Manometry biofeedback versus standard care
Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Control Manometry biofeed-
back versus standard
care
Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Complete
spontaneous
bowel move-
The mean num-
ber of complete
spontaneous
The mean number of
complete spontaneous
bowel movements in the
  52
(1 study)
⊕⊕⊝⊝
low1,2
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ments per
week at
three months
bowel move-
ments per week
in the control
group at three
months was 1.9
intervention group was
2.7 movements higher
(1.99 to 3.41 higher)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio; MD: Mean difference
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 High risk of bias in the included study due to open-label design.
2 Sparse data (52 patients).
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B A C K G R O U N D
Description of the condition
Constipation is a symptom-based disorder defined as, “unsatisfac-
tory defecation characterized by infrequent stools, difficult stool
passage, or both. Difficult stool passage includes straining, a sense
of difficulty passing stool, incomplete evacuation, hard lumpy
stools, prolonged time to stool or need for manual manoeuvres to
pass stool” (Brandt 2005). Chronic constipation is further defined
as the presence of these symptoms for at least six months. If inves-
tigations exclude all underlying bowel and other pathologies (e.g.
neurological or endocrine conditions, adverse effects of medica-
tion and immobility), that could be causing the constipation, then
the constipation is considered to be functional or idiopathic. Idio-
pathic constipation accounts for 75% of cases of chronic constipa-
tion (Gilliland 1997).
Two main types of idiopathic constipation have been distin-
guished: slow transit constipation and functional outlet obstruc-
tion or evacuation disorders (Bleijenberg 1994), which has also
been referred to in the literature as either spastic pelvic floor syn-
drome, pelvic floor dyssynergia, paradoxical puborectalis contrac-
tion or anismus. Outlet obstruction is thought to be due to abnor-
mal use of a normal pelvic floor. During straining, the puborectal-
is muscle contracts instead of relaxing and the anal canal remains
closed, preventing defecation (Bleijenberg 1994; Gilliland 1997). It
has also been suggested the problem is due to insufficient propul-
sive force being generated in the pelvis (Koutsomanis 1995). Slow
transit constipation is the result of a failure of peristalsis to move
faecal material through the colon at a normal rate. The aetiology of
slow transit constipation is unknown, but is likely to be multifacto-
rial and may differ across individuals.
Some patients exhibit both slow transit and functional outlet ob-
struction (Rieger 1997; Rao 1998). Constipation is a common prob-
lem in Western populations, with most studies identifying a preva-
lence of between 12 to 19% (Higgins 2004). The prevalence of
chronic idiopathic constipation is unknown. Chronic idiopathic
constipation can result in increased levels of anxiety, depression
and poor quality of life (Irvine 2002; Mason 2002; Cheng 2003).
Description of the intervention
Biofeedback is based on behaviour modification (Denis 1996). Gut
directed biofeedback retraining usually involves patients being
taught to defecate effectively using bracing of the abdominal wall
muscles and effective relaxation of the pelvic floor muscles (Em-
manuel 2001), with or without attempts to modify sensation in the
rectum. However, there is a wide variety of methods and protocols.
The first reports of biofeedback being used for the treatment of con-
stipation were published in 1981 and 1983 (Denis 1981; Van Baal
1983).
Biofeedback treatment for idiopathic constipation has since been
studied widely and is used to manage chronic idiopathic consti-
pation that is intractable and non-responsive to dietary manipula-
tion or laxatives. There are three main methods of monitoring the
function of the anus and providing biofeedback to patients. These
methods include electromyograph (EMG) biofeedback, manome-
try biofeedback and balloon sensory training (Bassotti 2004). None
of these methods have been shown to be consistently more effec-
tive than any other method (Chronic Constipation Task Force 2005).
During biofeedback sessions patients may also be given basic in-
struction on gut anatomy and function, as well as behavioural ad-
vice about frequency and length of toilet visits, posture on the toi-
let and dietary habits (Emmanuel 2001).
EMG biofeedback relies upon the display of a recording of elec-
tromyographic activity from the external anal sphincter and pelvic
floor or abdominal muscles or both on a computer monitor (Bas-
sotti 2004). Recordings may be made from electrodes placed within
the anal canal or from adhesive surface electrodes on the patient’s
perianal or perineal skin or abdominal muscles or both. The pa-
tient learns to relax the pelvic floor muscles initially by watching the
recording on a monitor and subsequently learns to 'push' to defe-
cate, while keeping these same muscles relaxed (Bassotti 2004).
Manometry biofeedback requires the insertion of a manometric
probe such as a pressure transducer, perfused catheter or balloon,
into the anal canal to measure anal canal pressure and contraction
and relaxation of the pelvic floor (Bassotti 2004). Contraction and
relaxation of the anal sphincters and pelvic floor is then displayed
on a computer monitor and training techniques are very similar to
those employed during EMG biofeedback.
Sensory training involves the patient learning to discriminate de-
creasing volumes in the rectum and to expel a simulated stool, usu-
ally an air or water-filled intrarectal balloon. Initially the balloon
may be inserted into the rectum, inflated and then withdrawn by
the therapist as the patient focuses on the sensations produced
and attempts to relax the pelvic floor and anal sphincters (Bassotti
2004). Later during the training the patient is expected to attempt
to pass the balloon independently to improve defecation. Two or
three different balloon systems are in use and sensory training may
be combined with manometry or EMG biofeedback.
How the intervention might work
The majority of biofeedback studies to date have focused on the
effectiveness of the therapy for patients with chronic idiopathic
constipation due to evacuation disorders, but the effectiveness of
biofeedback for chronic idiopathic constipation as a result of slow
gut transit has also been investigated (Chiotakaku-Faliakou 1998;
Emmanuel 2001; Battaglia 2004). Patients are enabled to recognise
the sensations associated with relaxation of the pelvic floor and
anus by a variety of different methods (Denis 1996), learn correct
use of abdominal muscles to create an effective pushing force and
thus learn to defecate effectively. Evacuating regularly may also
stimulate gut transit.
Why it is important to do this review
Non-randomised studies of biofeedback for idiopathic constipa-
tion have reported positive results and suggest that 33% to 90%
of patients improve following treatment (Fleshman 1992; Gilliland
1997; Coulter 2002; Heymen 2003; Chiarioni 2008). This has led to
the assertion that biofeedback is an effective intervention and the
treatment of choice for chronic idiopathic constipation occurring
as a result of both evacuation disorders and slow gut transit. How-
ever, there is an inherent risk of bias with case series and non-ran-
domised trials, which do not control for non-specific effects of an
intervention such as incidental advice and patient-therapist inter-
action. Non-randomised studies are more likely to show falsely pos-
itive and larger treatment effects than randomised controlled trials
(Guyatt 2008a). Potential biases, such as selection bias, confound-
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ing and reporting bias, are likely to occur in non-randomised stud-
ies. Effect sizes estimated from such exploratory non-randomised
trials have been used to inform power calculations for a minority
of subsequent randomised controlled trials included in this review
(Koutsomanis 1995; Glia 1997; Chiarioni 2006; Heymen 2007).
Few investigators have identified the possible 'placebo effect' that
the interaction with the biofeedback therapist may produce (Rao
1997). A systematic review is required to summarize the available
data on the efficacy of biofeedback for the treatment of chron-
ic idiopathic constipation. The aim of this review was to answer
the question: Does biofeedback decrease physical or psychological
morbidity and symptom distress and improve quality of life in pa-
tients with a diagnosis of chronic idiopathic (functional) constipa-
tion?
O B J E C T I V E S
The primary objective was to assess the efficacy and safety of
biofeedback for the treatment of chronic idiopathic (functional)
constipation in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) comparing one method of
biofeedback for constipation with sham treatment, conventional
treatment, no treatment or another method of biofeedback were
considered for inclusion. There were no language restrictions.
Types of participants
Male or female patients over 18 years of age with chronic idiopath-
ic (functional) constipation receiving care in a variety of healthcare
settings (hospital, community) were included. Chronic idiopathic
constipation can be defined using the Rome I, II or III criteria. Idio-
pathic constipation according to the Rome III criteria (Longstreth
2006), consists of two or more of the following symptoms for at least
3 months:
1. straining during at least 25% defecations;
2. lumpy or hard stools in at least 25% defecations;
3. sensation of incomplete evacuation for at least 25% defecations;
4. sensation of anorectal obstruction or blockage in at least 25%
defecations;
5. manual manoeuvres to facilitate at least 25% of defecations (e.g.
digital evacuation, support of the pelvic floor);
6. fewer than 3 defecations per week;
7. loose stools are rarely present without the use of laxatives; and
8.  insufficient criteria for a diagnosis of irritable bowel syndrome
(IBS).
To avoid missing studies that did not utilize Rome criteria the Amer-
ican College of Gastroenterology Chronic Constipation Task Force
definition of chronic constipation was also utilized (Brandt 2005).
Patients with constipation secondary to the use of constipating
medication or to conditions such as diabetes mellitus, long-term
neurological conditions, hypothyroidism, tumour, anal fissure as
well as acute constipation were excluded.
Types of interventions
Studies of biofeedback treatment for chronic idiopathic constipa-
tion were considered for inclusion.  All types of visual or auditory
biofeedback (e.g. EMG biofeedback, manometry biofeedback, bal-
loon sensory training) were considered. Biofeedback treatments
needed to be carried out by a qualified healthcare practitioner (e.g.
medical practitioner, nurse, physiotherapist), but could be carried
out in a primary, secondary or tertiary care setting.
Types of outcome measures
Primary outcomes
The primary outcome measures were global or clinical improve-
ment as defined by the included studies (e.g. constipation score,
clinical symptoms, frequency of defecation, straining, lumpy or
hard stools, sensation of incomplete evacuation, sensation of
anorectal blockage, manual manoeuvres to facilitate defecation,
pain, and bloating).
Secondary outcomes
Secondary outcome measures included:
- anxiety and depression;
- quality of life (QoL);
- need for rescue medication such as laxatives or rectal evacuants;
- gastrointestinal transit time measurement (e.g. using ra-
dio-opaque markers), functional recto-anal evaluation (proc-
toscopy, ano-rectal manometry, defecography) or electromyogra-
phy;
- cost effectiveness; and
- any adverse events.
Search methods for identification of studies
Electronic searches
The following databases were searched from inception to Decem-
ber 2013 to obtain relevant studies for this review.
• The Cochrane Central Register of Controlled Trials (CENTRAL).• The Cochrane Complementary Medicine Field.• The Cochrane Inflammatory Bowel Disease and Functional Bow-
el Disorders Group Specialized Register.• MEDLINE.• CINAHL (1982 to present).• British Nursing Index (1984 to present).• EMBASE (1980 to present).• PsychINFO (1989 to present).• SCOPUS.• Science Citation Index Expanded (SCI-EXPANDED) (1980-
present).• Social Sciences Citation Index (SSCI) (1980-present).• Conference Proceedings Citation Index - Social Science and Hu-
manities (CPCI-SSH) (1990-present).• Conference Proceedings Citation Index - Science (CPCI-S) (1990-
present).
MESH and keyword terms were modified as necessary for each
database. There were no language restrictions. The searches were
restricted by publication type to randomised controlled trials and
controlled clinical trials by applying the Cochrane highly sensi-
Biofeedback for treatment of chronic idiopathic constipation in adults (Review)
Copyright © 2014 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
11
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
tive search strategy for identifying randomised controlled trials in
MEDLINE: Ovid format (Lefebvre 2011). The latest search for this re-
view was conducted on 16 December 2013. The search strategies
for each database are reported in Appendix 1.
Searching other resources
The reference lists of identified randomised clinical trials and re-
view articles were checked in order to find randomised trials not
identified by the electronic searches. Ongoing trials were searched
through the websites www.controlled-trials.com and www.clini-
caltrials.gov. Grey literature was searched through the SIGLE and
GreyNet databases and other unpublished literature was obtained
through searches of conference proceedings as identified above.
Data collection and analysis
Selection of studies
Two authors (SW and CN) independently reviewed potentially rel-
evant studies to determine if they met the pre-specified inclusion
criteria. Any disagreement between authors was resolved by con-
sensus and if necessary by consultation with the third author (PC).
Data extraction and management
A standardized data extraction sheet was developed to record da-
ta on: study quality, study setting, participants (age and sex; how
diagnosis was confirmed; inclusion and exclusion criteria), inter-
ventions (type of biofeedback, administration, duration, regimen
of controlled intervention), outcome measures, attrition, inten-
tion-to-treat (ITT) analysis, duration of follow-up and the type and
number of any reported adverse events. Two authors (SW and CN)
independently extracted the data from each study. Any disagree-
ment was resolved by discussion and consensus with the third au-
thor (PC).
Assessment of risk of bias in included studies
The full text of all eligible studies was obtained for independent re-
view by two reviewers (SW and CN). Reviewers were not blinded as
to the authors of studies. The methodological quality of each study
was assessed and where necessary the study authors were contact-
ed for missing data or clarification of the published data.
The Cochrane risk of bias tool was used to assess the quality of ran-
domised controlled trials (Higgins 2011). Factors assessed includ-
ed:
• random sequence generation;• allocation concealment;• blinding;• incomplete outcome data;• selective outcome reporting; and• other potential sources of bias.
We rated each of these factors as ‘low risk’, ‘high risk’ or ‘unclear
risk’. Disagreements were resolved by consensus.
We used the GRADE approach to assess the overall quality of evi-
dence for the primary outcome and selected secondary outcomes
of interest. Outcomes from pooling of randomised trials start as
high quality evidence, but may be downgraded due to: (1) risk of
bias, (2) indirectness of evidence, (3) inconsistency (unexplained
heterogeneity), (4) imprecision (sparse data), and (5) reporting bias
(publication bias). The overall quality of evidence for each outcome
was determined after considering each of these elements, and cat-
egorized as high quality (i.e. further research is very unlikely to
change our confidence in the estimate of effect); moderate quality
(i.e. further research is likely to have an important impact on our
confidence in the estimate of effect and may change the estimate);
low quality (i.e. further research is very likely to have an important
impact on our confidence in the estimate of effect and is likely to
change the estimate); or very low quality (i.e. we are very uncertain
about the estimate) (Guyatt 2008b; Schünemann 2011).
Measures of treatment e;ect
The extracted data from the original studies were used to construct
two by two tables (e.g. clinical improvement versus no improve-
ment for biofeedback versus control). Where possible we calculat-
ed the risk ratio (RR) with corresponding 95% confidence intervals
(95% CI) for each dichotomous outcome and the mean difference
(MD) with corresponding 95% CI, however this was not possible
from the data presented.
Dealing with missing data
The authors of the included studies were contacted, where possi-
ble, to obtain any missing data. Where possible an ITT analysis was
used whereby any missing outcome data were assumed to be treat-
ment failures.
Data synthesis
Data were analysed using Review Manager (RevMan 5.2). Data from
individual trials were to be combined for meta-analysis if the in-
terventions, patient groups and outcomes were sufficiently similar
(determined by consensus). Data were not to be pooled for meta-
analysis if a high degree of heterogeneity was detected (i.e. I2 >
75%). A fixed-effect model was to be used to pool data in the ab-
sence of heterogeneity. A random-effects model was to be used if
significant heterogeneity was detected. The pooled RR and corre-
sponding 95% CI was to be calculated for dichotomous outcomes.
For continuous outcomes the pooled MD or SMD and 95% CI were
to be calculated as appropriate.
Subgroup analysis and investigation of heterogeneity
If a sufficient number of randomised trials were identified, the fol-
lowing subgroups analyses were planned:
1. duration of disease (less than 5 years, 5 to 10 years, more than
10 years);
2. constipation sub-type (slow-transit constipation without evacu-
ation disorder, slow transit constipation with evacuation disorder,
normal transit constipation with evacuation disorder); and
3. method of biofeedback (EMG, manometry, sensory training).     
Sensitivity analysis
A sensitivity analysis was planned to determine if the findings from
the primary analysis were changed by incorporating different trials
in the analysis.
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R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies and Characteristics of ongoing studies.
Results of the search
A total of 1232 results were obtained from the electronic search-
es, of which 98 were duplicated between the databases. The titles
and abstracts of the remaining 1134 results were read and 49 pa-
pers were considered for inclusion. The full papers of these 49 stud-
ies were read and 19 non-randomised studies, one RCT of biofeed-
back for anal pain (Chiarioni 2010), and one letter were excluded,
leaving a total of 25 individual reports of 17 randomised studies for
inclusion in the review (Figure 1). Studies reported as an abstract
were only included where no full published paper was available (Hu
2006; Jung 2007).
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Figure 1.   Figure 1: Study flow diagram.
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Figure 1.   (Continued)
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Included studies
Seventeen individual randomised controlled trials (with a total of
931 participants) of biofeedback for chronic idiopathic constipa-
tion were identified (See characteristics of included studies). Seven
studies were identified comparing biofeedback with 'conventional'
non-surgical treatment (You 2001; Chiarioni 2006; Hu 2006; Heymen
2007; Farid 2009; Simon 2009; Hart 2012). Six studies compared
one method of biofeedback with another method of biofeedback
(Bleijenberg 1994; Koutsomanis 1995; Glia 1997; Heymen 1999;
Chang 2003; Pourmomeny 2010). Two studies compared biofeed-
back with a less conventional surgical intervention (Lehur 2008;
Faried 2010). One study compared manometry biofeedback for
constipation with sham treatment (Rao 2007), and reported long-
term follow up separately (Rao 2010). One crossover study com-
pared electrical stimulation to biofeedback (Jung 2007). No studies
compared biofeedback with no treatment. It is apparent that the
lead author Farid and Faried are the same individual, but it is un-
clear which is the correct spelling of the name.
Sample sizes
Sample sizes ranged from 21 to 109 randomised subjects with a
mean of 48 subjects per study (Bleijenberg 1994; Chiarioni 2006;
Hart 2012).
Settings
All seventeen randomised studies were conducted within sec-
ondary or tertiary specialist health care settings and all participants
had been referred to this service. No studies were identified that
had been conducted in primary care settings. It is likely that pa-
tients referred to secondary or tertiary settings have more severe
constipation, are more needy and bothered by their symptoms, and
seek health care more than those in community settings (Simren
2001; Simren 2006). Therefore it would be difficult to generalise the
results from these studies to other populations. However, it is likely
that the participants in these studies are at least representative of
patients referred to specialist centres with chronic idiopathic con-
stipation. The studies were conducted in a range of countries. Four
studies were conducted in the US, two in each of Korea and Egypt
and one each in Iran, Spain, the Netherlands, the UK, Sweden, Tai-
wan and Italy. There was only one international study (Lehur 2008),
which was conducted at three centres in Europe in Italy, France and
the UK. The country of origin was unclear for one study (Hu 2006).
Participants
All participants were diagnosed with chronic idiopathic constipa-
tion and most had dyssynergic defecation. Most patients were re-
ported as having failed conservative medical management with di-
etary fibre and laxatives. However, the failure of conservative med-
ical management was not determined systematically or consistent-
ly across all studies. Heymen 2007 utilized a four week 'run-in'
period involving education regarding dietary manipulation, exer-
cise, fluid intake, bowel function and correct defecation technique
and only recruited patients who failed to improve after the run-
in period. Chiarioni 2006 administered a 30 day trial of laxatives
in patients who were unresponsive to standard treatment. No oth-
er study reported on baseline status or previous intervention fail-
ure apart from patient self-report of failure of standard care. There
was little consistency in selection criteria for participants and many
studies did not report detailed sociodemographics or constipation
history for study participants. Eight-two per cent of participants
were women (764/931). Ages ranged from 18 to 82 years, but da-
ta were not reported in a format that allowed the calculation of a
mean age.
Eight studies used Rome (I, II or III) criteria for chronic constipation
or dyssynergic defecation to determine eligibility of participants for
inclusion (Glia 1997; Chang 2003; Chiarioni 2006; Hu 2006; Heymen
2007; Rao 2007; Farid 2009; Simon 2009). Eight studies had includ-
ed only patients with constipation as a result of an evacuation dis-
order (pelvic floor dyssynergia) (Bleijenberg 1994; Heymen 1999;
Chiarioni 2006; Heymen 2007; Rao 2007; Farid 2009; Simon 2009;
Hart 2012), one study report stated it included patients with slow
transit constipation in addition to pelvic floor dyssynergia (Koutso-
manis 1995), while one study included only patients with slow tran-
sit constipation (You 2001).
Eight studies reported that the randomised groups were compa-
rable in terms of sociodemographics and constipation history at
baseline (Bleijenberg 1994; Koutsomanis 1995; Chang 2003; Chiar-
ioni 2006; Jung 2007; Heymen 2007; Simon 2009; Faried 2010).
Six studies failed to report baseline comparability between groups
(Glia 1997; Heymen 1999; You 2001; Hu 2006; Farid 2009; Pourmo-
meny 2010). Rao 2007 reported that patients in the biofeedback
group differed significantly from the other groups at baseline for
anorectal manometry findings (i.e. higher mean resting sphincter
pressure (P = 0.02), mean anal residual pressure (P = 0.0067) and
higher threshold for first perception (P = 0.01)) than controls (Rao
2007). Hart 2012 reported baseline characteristics, but did not com-
ment on the comparison between groups, even though some in-
equalities were evident. Lehur 2008 reported that the baseline 'ob-
structed defecation score' of the evaluable populations differed be-
tween biofeedback and surgical (STARR) treatment groups due to
high attrition in the biofeedback arm. However, the statistical sig-
nificance of this difference was not reported or discussed.
It is noted that Farid 2009 report screening consecutive patients
referred to the same institution over the same time period as the
Faried 2010 study, with identical demographics reported for both
studies. This suggests that the two manuscripts report the results
of the same study, however, with major inconsistencies in report-
ing details. This is a major concern. Attempts to obtain clarification
from the authors on this point were unsuccessful and we could find
no published comments from other specialist clinicians on these
studies.
Interventions
No two studies included used the same protocol for biofeedback.
EMG biofeedback was used in eleven studies (Bleijenberg 1994;
Koutsomanis 1995; Heymen 1999; Chang 2003; Chiarioni 2006; Hey-
men 2007; Jung 2007; Lehur 2008; Simon 2009; Pourmomeny 2010;
Hart 2012). Within these studies some investigators used perianal
skin surface EMG electrodes (Koutsomanis 1995), while others de-
livered the EMG training by using a visual display from an anal probe
electrode (Bleijenberg 1994; Heymen 1999; Heymen 2007; Jung
2007; Hart 2012). Manometry biofeedback was used in two studies
(Glia 1997; Rao 2007). Balloon sensory training was used in three
studies (Hu 2006; Farid 2009; Faried 2010). The type of biofeedback
used in one study was unclear (You 2001). Three studies incorpo-
rated education regarding normal bowel function, dietary manipu-
lation and lifestyle advice and considered this an essential compo-
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nent of the biofeedback intervention (Heymen 1999; Heymen 2007;
Farid 2009), while in four studies this was referred to as standard
care and therefore a control intervention (Chiarioni 2006; Hu 2006;
Rao 2007; Simon 2009).
The number, frequency and duration of biofeedback sessions also
varied between studies. The number of biofeedback training ses-
sions ranged from a minimum of five (Chiarioni 2006) to a maximum
of fourteen (You 2001). The frequency of biofeedback sessions var-
ied from daily sessions (You 2001) to sessions once every fortnight
(Rao 2007; Heymen 2007). Most of the included studies did not re-
port the length of each biofeedback session. The total duration of
the biofeedback intervention ranged from two weeks (You 2001) to
three months (Rao 2007; Heymen 2007; Hart 2012). See the Charac-
teristics of included studies tables for more details on the interven-
tions used in each study.
Outcomes
Most investigators used some sort of symptom scoring system as
an outcome, but these 'scores' did not necessarily assess the same
symptoms. Only one study used a validated symptom outcome
score with sound psychometric properties to assess the effective-
ness of biofeedback (Heymen 2007). This was the patient assess-
ment of constipation symptoms (PAC-SYM) questionnaire (Frank
1999). Eleven studies included a patient reported outcome mea-
sure (PROM) evaluating the patient’s perception of change in, or re-
lief from, symptoms (Bleijenberg 1994; Glia 1997; You 2001; Chang
2003; Chiarioni 2006; Heymen 2007; Rao 2007; Jung 2007; Farid
2009; Faried 2010; Hart 2012). A PROM was used as the primary out-
come measure in five of the included studies (Chiarioni 2006; Hey-
men 2007; Rao 2007; Faried 2010; Hart 2012). In these studies symp-
tom diaries and questionnaires were used to assess the presence
of abdominal pain, straining at stool, feeling of incomplete evacu-
ation, frequency of unassisted bowel motions and laxative use. The
United States Food and Drug Administration (FDA) has identified
complete spontaneous bowel movements (CSBM) as the preferred
patient-reported outcome, recommending this as the primary end-
point for registry trials of constipation treatments. However, this
has only recently been recommended and only one study utilized
this outcome (Rao 2007).
Some studies specified a pre-determined level of improvement in
symptoms that was required before the patient was considered to
have a good clinical outcome (Bleijenberg 1994; Lehur 2008; Farid
2009; Faried 2010). Treatment success was defined as a 50% im-
provement in post-treatment scores compared to baseline scores
in two studies (Bleijenberg 1994; Lehur 2008). Treatment success
was defined as a return to a 'normal bowel habit' in two studies
(Farid 2009; Faried 2010). Most studies used a combination of out-
come measures, such as symptom assessment, patient global re-
port of satisfaction, anorectal manometry and QoL. Only five stud-
ies pre-specified primary outcome measures (Chiarioni 2006; Hey-
men 2007; Rao 2007; Lehur 2008; Faried 2010).
The length of follow-up varied across the 17 included studies. Four
studies did not follow participants beyond the completion of the in-
tervention (Heymen 1999; Chang 2003; Hu 2006; Hart 2012). Chiar-
ioni 2006 followed patients for up to 24 months after completion of
the intervention. Seven studies reported following patients for one
year after completion of the biofeedback intervention (You 2001;
Chiarioni 2006; Heymen 2007; Rao 2007; Lehur 2008; Farid 2009;
Faried 2010).
Five studies did not report outcomes in a format suitable for the
production of forest plots within RevMan (Heymen 1999; Hu 2006;
Jung 2007; Simon 2009; Pourmomeny 2010). No meta-analyses
were possible as study populations, interventions and outcomes
were too heterogeneous. As a result planned subgroup and sensi-
tivity analyses were not performed. See the Characteristics of in-
cluded studies tables for more details on the outcome measures
used in each study.
Excluded studies
Twenty-one studies, including 19 non-randomised trials, one RCT
of biofeedback for anal pain (Chiarioni 2010), and one letter (Chiar-
ioni 2007), were excluded. See the Characteristics of excluded stud-
ies tables for further details.
Risk of bias in included studies
No studies had a low risk of bias for all categories that were as-
sessed. The overall results of the risk of bias assessment are sum-
marised in Figure 2.
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Figure 2.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.
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Figure 2.   (Continued)
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Overall, random sequence generation was judged to be at low risk
of bias in only five studies (Glia 1997; Chiarioni 2006; Rao 2007;
Faried 2010; Hart 2012), at high risk of bias in one study (Pourmo-
meny 2010) and at an unclear risk of bias in the remaining 11 stud-
ies. Allocation concealment was judged to be adequate in six stud-
ies (Koutsomanis 1995; Glia 1997; Chiarioni 2006; Rao 2007; Farid
2009; Faried 2010), and unclear for the remaining eleven studies.
Blinding carried a high risk of bias in all but one study which was
rated unclear (Jung 2007). Incomplete outcome data carried a high
risk of bias for four studies (Glia 1997; Hu 2006; Lehur 2008; Hart
2012), an unclear risk for three studies (Jung 2007; Rao 2007; Pour-
momeny 2010), and a low risk for the remaining ten studies.
Allocation
Seven studies were considered to have adequate random sequence
generation, reporting that the allocation sequence was generated
randomly by a computer (Koutsomanis 1995; Glia 1997; Rao 2007;
Farid 2009; Faried 2010; Hart 2012), or by shuffling sealed opaque
envelopes containing the allocation (Chiarioni 2006). However, for
the remaining included studies the method used for generation of
the allocation sequence was not reported and these studies were
rated as unclear risk of bias for this item.
Six studies reported adequate allocation concealment and used
sealed opaque envelopes prior to allocation (Koutsomanis 1995;
Glia 1997; Chiarioni 2006; Rao 2007; Farid 2009; Faried 2010). In the
remaining studies the method used for allocation concealment was
not described and these studies were rated as unclear risk of bias
for this item.
Blinding
Sixteen of 17 included studies were judged to be at high risk of bias
for blinding of participants and personnel. One study compared
biofeedback with a sham treatment (Rao 2007), but participants
were not blinded as to whether they were receiving biofeedback or
sham biofeedback. Blinding was partially maintained between oral
diazepam and placebo tablet in one study (Heymen 2007), howev-
er, participants were not blinded as to whether they were receiving
biofeedback or oral tablets. One study was rated as unclear risk of
bias for blinding because it was an abstract publication that did not
provide any details (Jung 2007). It is acknowledged that it is diffi-
cult to blind either participants or therapists in behavioural studies,
however outcome assessors could have remained blind to treat-
ment allocation.
Incomplete outcome data
The use of an intent-to-treat analysis was reported in five studies
(Chiarioni 2006; Heymen 2007; Rao 2007; Lehur 2008; Farid 2009).
Three studies were judged to be at high risk of bias due to high rates
of attrition (Glia 1997; Rao 2007; Farid 2009).
Selective reporting
No studies were judged to be at high risk of bias for selective report-
ing. Two studies were judged to be at low risk for selective reporting
because these trials were registered on a clinical trials registry (Rao
2007; Hart 2012). Studies that were not registered on a clinical trials
registry were rated as unclear risk of bias for selective reporting. For
most studies it was difficult to determine whether outcomes were
reported selectively, as the authors had not registered the trial or
published the protocol in advance of publishing the findings. Selec-
tive outcome reporting was suspected when studies only reported
findings from patients who completed the trial and did not report
attrition or losses to follow-up from the study. It was also consid-
ered where an ITT analysis was not conducted.
Other potential sources of bias
Four studies reported that power calculations were conducted to
determine required sample sizes (Koutsomanis 1995; Glia 1997;
Chiarioni 2006; Heymen 2007). It is possible that the remaining
studies were not sufficiently powered to detect a difference in effi-
cacy between treatment groups. While a total of 931 patients were
studied overall, the sample sizes in most studies were small. How-
ever, it is acknowledged that it may be difficult to recruit large num-
bers of patients to behavioural therapy trials. There is also a chance
that some of the studies suffered from poor recruitment, although
as a CONSORT flowchart was included in only two studies this was
difficult to determine (Chiarioni 2006; Heymen 2007). However it
seems unlikely that, for example, that Heymen and colleagues set
out to undertake a four arm RCT study including only 36 partici-
pants (Heymen 1999). It is also interesting to note that Faried 2010
appeared to only see 62 eligible 'consecutive' participants over a
period of three years and four months, recruiting 60 of these pa-
tients to their study, which suggests a low referral rate or slow re-
cruitment. In addition it is noted that the authors report screen-
ing consecutive patients referred to the same institution over the
same time period, with identical demographics, for both Farid 2009
(biofeedback and botulinum toxin-A arms) and for Faried 2010, sug-
gesting that the two manuscripts report the results of the same
study, however with major inconsistencies in reporting details. This
is a major concern and the findings of these two studies need to
be interpreted with caution. One study was stopped early due to
poor recruitment which may have been influenced by one of the
trial arms involving a surgical intervention and patient preference
(Lehur 2008). Both trials that were registered on a recognised online
trial database in advance of recruitment did not report the expect-
ed enrolment so it is impossible to determine if the target recruit-
ment was achieved or not (Heymen 2007; Rao 2007). Both of these
studies included CONSORT flowcharts and subsequent communi-
cation confirms that Rao 2007 performed power calculations. How-
ever, these details were not reported a priori or within the original
study report so it was unclear whether the study recruited to target.
The treatment groups were unequal at baseline in one study with
participants who received biofeedback having worse symptoms at
baseline than the sham biofeedback group (Rao 2007). These symp-
toms included a 'significantly lower defecation index' and 'relative-
ly greater pelvic floor dysfunction' in the biofeedback group (Rao
2007). Bias could have been introduced as a result. For example
the biofeedback group could have perceived an increased bene-
fit over the sham group as they had worse symptoms to start with
and therefore there was more room for improvement. This same
study used balloon distention 'to promote awareness for stooling
and match the sensory conditioning provided under biofeedback'
as a sham treatment, which could have had a therapeutic effect
(Rao 2007). As such, the difference in effect size between the two
groups may be less than expected than if the sham treatment had
no therapeutic effect. The same issue affected Simon 2009, where
the control group (EMG assessment of straining) would be consid-
ered a form of biofeedback by many, although it was unclear if the
patient saw the monitor or not.
Heymen 2007 reported that patients declined to participate due to
lack of time to attend the hospital for appointments, travel difficul-
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ties, or wanting to have an alternative treatment. This could have
led to a sample being recruited that was not representative of the
population of interest. In addition, Heymen 2007 did not report if
the characteristics of patients who were not given biofeedback fol-
lowing the run-in period differed from those who remained in the
study and went on to receive the intervention. Patients with a more
intractable constipation problem could therefore have been en-
tered into the second phase of the study, which tested the biofeed-
back intervention, and may therefore have been less likely to re-
spond to treatment. This could have led to an underestimation of
the effect of the intervention.
In one study there was a disproportionate number of male
(n=11/22; 50%) participants compared to the usual population
of patients who would be referred to a tertiary treatment centre
(Chang 2003). It is not clear whether men respond differently to
biofeedback than women, but this sample was certainly not repre-
sentative of the population of interest.
E;ects of interventions
See: Summary of findings for the main comparison Balloon sen-
sory training biofeedback versus surgery for chronic constipation;
Summary of findings 2 Balloon sensory training biofeedback ver-
sus botulinum toxin-A for chronic constipation; Summary of find-
ings 3 EMG biofeedback versus diazepam for chronic constipation;
Summary of findings 4 EMG biofeedback versus STARR procedure
for obstructed defecation; Summary of findings 5 EMG biofeed-
back versus laxative for chronic constipation; Summary of find-
ings 6 Manometry biofeedback versus sham biofeedback for chron-
ic constipation; Summary of findings 7 Manometry biofeedback
versus standard care for chronic constipation
Several of the included studies concluded that biofeedback provid-
ed a benefit for patients with chronic idiopathic constipation with
effect sizes ranging from 40% to 100% of patients (Koutsomanis
1995; Glia 1997). It was not always possible to identify the percent-
age of patients who improved as some studies only reported that
differences were statistically significant and did not report the pro-
portions improved in each group.
Studies comparing one method of biofeedback with no treat-
ment
No studies comparing biofeedback to a no treatment control were
found.
Studies comparing one method of biofeedback with sham
biofeedback
Rao 2007 investigated the effectiveness of manometry biofeedback
compared to a sham treatment and found that patients who re-
ceived biofeedback had a statistically significant increase in the
number of 'complete spontaneous bowel movements' per week
compared to baseline (P < 0.02), and sham biofeedback (P < 0.05).
The mean number of complete spontaneous bowel movements per
week at three months was 4.6 in the biofeedback group compared
to 2.8 in the sham biofeedback group (MD 1.80, 95% CI 1.25 to 2.35).
Statistically significant improvement in global bowel satisfaction
was found in all groups (P < 0.0001) and the dyssynergic pattern was
corrected in 79% of biofeedback recipients, 4% of sham and 8.3% of
standard treatment recipients respectively (P < 0.001). Long-term
follow-up from this initial study is reported in a separate paper
(Rao 2010).The original paper reported that 77 subjects were ran-
domised to three arms. The longer term follow-up report excludes
the sham arm (Rao 2010). From 77 people originally randomised,
the one year follow-up was reported for only 20 patients.
Studies comparing one method of biofeedback with another
treatment for constipation (e.g. laxatives, education, diet ma-
nipulation, botulinum toxin-A, surgery)
Ten studies compared biofeedback with other medical or surgi-
cal treatment. These treatments included 'standard care' and laxa-
tives, botulinum toxin-A injection, diazepam and surgical interven-
tions. Some of these interventions including botulinum toxin-A in-
jection, diazepam and surgery are not widely used, although they
considered to be 'conventional' by the reporting authors.
Hu 2006 reported that balloon sensory training biofeedback was
an effective treatment for functional constipation. The study com-
pared balloon sensory training to dietary and lifestyle advice (Hu
2006). After treatment the number of spontaneous bowel move-
ments increased similarly in both groups. There was a decrease in
bloating, incomplete evacuation, straining and rescue laxative use
in the biofeedback group, but not in the control group. Detailed
findings were not reported in this abstract so data extraction was
not possible.
Rao 2007 compared manometry biofeedback to standard thera-
py consisting of diet, exercise and laxatives. Patients who received
biofeedback had a statistically significant increase in the number
of complete spontaneous bowel movements per week compared
to a standard care group (P = 0.006). The mean number of com-
plete spontaneous bowel movements per week at three months
was 4.6 in the biofeedback group compared to 1.9 in the standard
care group (MD 2.70, 95% CI 1.99 to 3.41).
Chiarioni 2006 reported EMG biofeedback to be significantly su-
perior  to conventional treatment with laxatives and dietary and
lifestyle advice. This study found that at both 6 and 12 months
80% (43/54) of biofeedback patients reported clinical improvement
compared to 22% (12/55) laxative-treated patients (RR 3.65, 95% CI
2.17 to 6.13). Over 50% of patients on laxatives self-reported that
they were worse or had no change in symptoms compared 15% of
the biofeedback group (P < 0.001). The biofeedback group had sig-
nificantly less straining (P < 0.01) and incomplete evacuation (P <
0.01) compared to patients in the laxative group. Paradoxical con-
traction on EMG was significantly reduced in the biofeedback group
compared to the laxative group (P < 0.001). Patients using digita-
tion were less likely to benefit from biofeedback (P = 0.013) and a
logistic regression analysis found digitation to be the only signifi-
cant independent predictor of clinical improvement at six months.
This study also demonstrated that the effects of biofeedback were
mostly maintained for up to two years following the completion of
treatment, without further training.
Simon 2009 compared EMG biofeedback to a control intervention
of 'counselling sessions' focusing on behavioural mechanisms in-
volved in defecation equivalent to the contact time for biofeedback
(Simon 2009). The authors reported a statistically significant differ-
ence between biofeedback and control in the frequency of defeca-
tions per week, EMG activity during straining to defecate and anis-
mus index. No data extraction was possible from this study.
Jung 2007 compared an unspecified biofeedback treatment to
electrical stimulation and found no significant differences in clini-
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cal improvement between the groups. No data extraction was pos-
sible from this abstract.
Hart 2012 compared EMG biofeedback to a control intervention
during which participants were trained to relax the temporalis or
trapezius muscles using feedback from EMG surface electrodes
placed over the corresponding muscles. From 81 patients who met
eligibility criteria 10 were randomised to receive biofeedback and
11 were randomised to the control group. The primary outcome
was constipation severity using a 'constipation severity index' de-
veloped by the authors. Quality of life was assessed as a secondary
outcome using the Irritable Bowel Syndrome Quality of Life Scale.
There were no statistically significant differences in constipation
severity or quality of life between the biofeedback and control
groups. The mean constipation severity score in the biofeedback
group was 30 compared to 34.9 in the muscle relaxation control
group (MD -4.90 95% CI -17.23 to 7.43). The mean quality of life score
in the biofeedback group was 96.1 compared to 96.7 in the control
group (MD -0.60, 95% CI -38.75 to 37.55).
Biofeedback has been compared with both botulinum toxin-A in-
jections and posterior myomectomy of the internal anal sphinc-
ter and puborectalis muscles for people with evacuation difficul-
ty, although it was unclear whether the biofeedback was provid-
ed via a manometry or EMG device (You 2001). You 2001 found
that 35 of 40 (88%) biofeedback patients had 'satisfactory improve-
ment' in constipation complaints, compared to 20 of 20 Botulinum
toxin-A patients (RR 0.89, 95% CI 0.77 to 1.02). Fourteen patients
had some flatus or faecal incontinence following the administra-
tion of botulinum toxin-A. No mortality or morbidity was report-
ed in the myomectomy group. Eight-eight per cent (35/40) of pa-
tients in the biofeedback improved clinically compared to 85% of
patients (17/20) in the myomectomy group (RR 1.03, 95% CI 0.83
to 1.28). Thirty-five biofeedback patients who reported improve-
ment in constipation symptoms had no relapse after two years fol-
low-up. The authors concluded that biofeedback was superior to
both botulinum toxin-A and myomectomy, but presented no statis-
tical analysis to support this assertion.
Farid 2009 compared the effectiveness of sensory training biofeed-
back versus botulinum toxin-A injections into the external anal
sphincter and puborectalis muscles. Initial improvement was
found in 12 patients (50%) of the biofeedback group, but only main-
tained in 6 (25%) at 1 year follow-up. Initial improvement was found
in 17 (70.83%) of botulinum toxin-A group, but only maintained in 8
(33.3%) long-term. Botulinum toxin-A was found to perform signifi-
cantly better than biofeedback initially but there was no statistical-
ly significant difference at one year (RR 0.75, 95% CI 0.31 to 1.83).
Straining symptoms had improved in both groups post-treatment
(P = 0.04 for biofeedback; P = 0.007 for botulinum toxin-A), but there
was no significant difference between groups. Significant improve-
ment was found for the outcomes manometric relaxation (biofeed-
back P = 0.04, botulinum toxin-A P = 0.001), and balloon expulsion
(biofeedback P = 0.01, botulinum toxin-A P = 0.001) but there was
no statistically significant difference between treatment groups. 
This same group (Faried 2010) also reported a comparison of
biofeedback with both botulinum toxin-A injections and a surgi-
cal intervention (bilateral open partial division of puborectalis). Re-
cruitment was slow and there was a risk of selection bias due to pa-
tient preference. Initial improvement was found in 50% of biofeed-
back patients (10/20), compared to 75% of botulinum toxin-A pa-
tients (15/20) and 95% of surgery patients (19/20). Surgery was sig-
nificantly better than biofeedback at one month (P = 0.006) and one
year (P = 0.02). The number of patients with improved constipation
at one year was 30% in the biofeedback group compared to 70% in
the surgery group (RR 0.43 95% CI 0.21 to 0.89). The mean constipa-
tion score at one year was 16.1 in the biofeedback group compared
to 10.5 in the surgery group (MD 5.60, 95% CI 4.67 to 6.53). Satis-
faction with treatment was reported in 6/20 (30%) of the biofeed-
back, 7/20 (35%) botulinum toxin-A and 14/20 (70%) surgery pa-
tients (P < 0.05), but there was a high rate of adverse reactions in
the surgery group: 3 infections, 2 incontinence, 2 intussusception
(n = 7/20) but not reported for other groups. The authors concluded
that the surgical intervention was superior to biofeedback, in spite
of a high level of adverse reactions to surgery in seven of the twen-
ty patients who underwent the procedure. There was no statisti-
cally significant difference in the proportion of botulinum toxin-A
or biofeedback patients reporting improvement in symptoms at
one year. Thirty per cent of biofeedback patients reported improve-
ment of symptoms at one year compared to 35% of botulinum tox-
in-A patients (RR 0.86, 95% CI 0.35 to 2.10). There was a statistically
significant difference in constipation score at one year. The mean
constipation score in the biofeedback group was 16.1 compared to
14.3 in the botulinum toxin-A group (MD 1.80, 95% CI 0.87 to 2.73).
In one other study of biofeedback was compared with a surgi-
cal intervention (stapled transanal rectal resection (STARR)) (Lehur
2008). Successful treatment, defined as a decrease in the obstruct-
ed defecation score of > 50% at one year was reported in 33% of
biofeedback patients compared to 82% of STARR patients (RR 0.41,
95% CI 0.26 to 0.65). The mean obstructed defecation score at one
year was 10.2 in the biofeedback group compared to 4.7 in the
STARR group (MD 5.50, 95% CI 3.44 to 7.56). Benefits of both treat-
ments were apparent at the end of treatment. PAC-QOL improved
in both groups at 12 months STARR (P < 0.0001) versus biofeed-
back (P = 0.002), but adverse events occurred in 8 (15%) STARR
patients (infection, pain, incontinence, bleeding, UTI, depression),
while only one biofeedback patient experienced anal pain. In some
cases the bleeding constituted a serious adverse event, requiring
further surgery. The authors concluded that surgery was superior
to biofeedback in spite of high level of often serious adverse re-
actions (infection, pain, faecal incontinence, bleeding and depres-
sion) among the patients who underwent surgery. It is notable that
25% of biofeedback patients (13/52) withdrew before the end of
treatment, most citing unsatisfactory results, and were excluded
from the analysis.
Heymen 2007 conducted the only study comparing the effective-
ness of EMG biofeedback with oral diazepam or a placebo tablet.
Biofeedback was reported to be significantly better than both di-
azepam (P < 0.001) and placebo (P = 0.017) at three month fol-
low-up. Seventy per cent (21/30) of biofeedback patients had im-
proved constipation at three month follow-up compared to 23%
(7/30) of diazepam patients (RR 3.00, 95% CI 1.51 to 5.98). Biofeed-
back patients had significantly increased unassisted bowel move-
ments (P = 0.016) and QoL scores were improved following biofeed-
back on both SF-36 and PAC-QOL compared to the other two
groups, but not significantly. EMG findings showed significantly
lower activity during straining following biofeedback (P < 0.001)
compared with diazepam.
No further data extraction or pooling of data were possible from
these studies.
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Studies comparing one method of biofeedback with another
method of biofeedback
Six studies comparing one method of biofeedback with another
method have been published.
All six were poor quality studies with high risk of bias (Bleijenberg
1994; Koutsomanis 1995; Glia 1997; Heymen 1999; Chang 2003;
Pourmomeny 2010). Bleijenberg 1994 found EMG biofeedback to
be superior to balloon sensory training for clinical improvement,
although the difference was not statistically significant. Seven-
ty-three per cent (8/11) of patients in the EMG biofeedback group
improved clinically compared to 22% (2/9) of patients in the bal-
loon sensory training group (RR 3.27, 95% CI 0.91 to 11.71). The au-
thors concluded that EMG biofeedback was more effective than ei-
ther manometry or balloon training methods of biofeedback  and
that education and balloon training alone is not sufficient (Bleijen-
berg 1994). Further data extraction was not possible due to the high
risk of bias and the confusion over the reporting of statistical results
from the tests applied in this study (Bleijenberg 1994).
A cross-over design was reported in another study (Koutsoman-
is 1995), whereby participants crossed over to the alternate treat-
ment arm if they did not improve after two sessions. There were
no statistically significant group differences in the frequency of
bowel movements, straining or other clinical symptoms. Sixty-two
per cent (18/29) of patients who underwent EMG biofeedback with
computer visual display reported clinical improvement compared
to 53% of patients (16/30)who underwent balloon sensory training
with no visual feedback (RR 1.16. 95% CI 0.75 to 1.81). Koutsoman-
is 1995 concluded that EMG biofeedback was equally effective with
or without visual biofeedback. However this study compared two
different methods of biofeedback rather than the emphasis being
on the visual display of muscle contraction.
Glia 1997 found no statistically significant difference in effective-
ness between manometry and EMG biofeedback (Glia 1997). Eighty
per cent (8/10) of patients who received EMG biofeedback report-
ed improvement in symptoms compared to 60% (6/10) of patients
who received manometry biofeedback (RR 1.33, 95% CI 0.74 to
2.41).
Heymen 1999 randomised patients to one of four groups: 1. EMG
biofeedback; 2. EMG biofeedback plus balloon sensory training; 3:
EMG biofeedback plus home EMG trainer; 4: EMG biofeedback plus
balloon sensory training plus home EMG trainer. Heymen 1999 re-
ported a statistically significant increase in unassisted bowel move-
ments in groups 1, 2 and 4, and a significant reduction in the use of
cathartics in groups 1, 2 and 3. However, the authors did not com-
pare differences across the four groups but rather compared the ef-
fects of treatment within each group individually. The authors con-
cluded that neither the addition of a home training device or bal-
loon sensory training improves outcomes over EMG biofeedback
alone (Heymen 1999). No data extraction was possible from this
study.
Chang 2003 assessed the effectiveness of biofeedback compared
to electrical stimulation using an anal plug and pulse generator.
Ten patients underwent EMG biofeedback and 12 patients received
electrical stimulation therapy (EST). The primary outcome was
bowel satisfaction which was calculated using a visual analogue
scale. No statistically significant difference in mean bowel satisfac-
tion scores was found. The mean bowel satisfaction score in the
biofeedback group was 59 (+/- 28.8) compared to 48.3 (+/- 34.1) in
the EST group (MD 10.70, 95% CI -15.58 to 36.98).
Pourmomeny 2010 reported more rapid balloon expulsion, an in-
creased volume of balloon expelled and an increased reported
sense of satisfaction with defecation in the biofeedback group com-
pared to the balloon training only group. However they only re-
port within group comparisons and no data extraction was possi-
ble from this study.
D I S C U S S I O N
There was a wide variation among the included studies in the type
of participants, interventions, use of outcome measures, duration
of treatment and length of follow-up. Many of the included stud-
ies were likely to be underpowered to detect differences between
groups. These findings are similar to those of a review of studies
of biofeedback for the management of faecal incontinence (Norton
2012).
Studies to date have only been undertaken within specialist or ter-
tiary care settings and populations. Further research is required,
particularly within primary care populations. There is now some
consensus that the Rome criteria (Thompson 1999; Longstreth
2006), should be used to confirm the diagnosis of chronic idiopath-
ic constipation for inclusion criteria in randomised controlled tri-
als. However, not all of the included studies in this systematic re-
view applied these criteria to the selection of participants. While
use of Rome criteria has been recommended to produce homoge-
neous samples for research, it has recently been shown that the
Rome criteria do not adequately differentiate between idiopathic
constipation and irritable bowel syndrome (Wong 2010). Some ex-
pert opinion suggests that biofeedback should only be offered to
those patients with dyssynergic defecation (Rao 2008). Diagnostic
criteria for dyssynergia were inconsistent among the studies that
included these patients. There was some consensus regarding the
results from the different investigations that would be considered
diagnostic of the condition, i.e. the patient would be unable to ex-
pel a water filled balloon (simulated stool), EMG would reveal in-
creased pelvic floor muscle activity during straining and defecog-
raphy would reveal a lack of increase in the anorectal angle dur-
ing straining. However, these investigations were applied inconsis-
tently among the different studies and there is as yet no clear con-
sensus as to which investigations should be used, or indeed the
clinical significance of abnormal findings. Some authors also in-
cluded delayed gut transit as a diagnostic criterion for diagnosis of
dyssynergia, although delayed gut transit is not unique to patients
with a dyssynergic pattern of defecation and thus cannot be con-
sidered diagnostic (You 2001; Rao 2007; Farid 2009; Faried 2010).
There is a lack of standardisation of physiological tests (anorectal
manometry, balloon expulsion and electromyographical assess-
ment), making results difficult to compare between different cen-
tres (Rao 2008; Scott 2008; Bharucha 2010). There is also a lack of
data regarding normal values, especially regarding age and gender
influences on function (Scott 2008), which makes the use of these
tests in research studies less helpful.
Numerous outcome measures were used to assess the effective-
ness of biofeedback in the included studies and as yet there is a
lack of evidence as to which outcome measures are the most ap-
propriate. This finding is similar to the results of the systematic re-
view by Koh and colleagues who also identified that few trials had
clearly defined primary and secondary outcomes (Koh 2008). Many
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studies also used multiple outcome measures, often without spec-
ifying which was the primary outcome measure, which increases
the risk of introducing a type I error (false positive result). There is
a clear lack of consensus as to the most appropriate outcome mea-
sures for assessment of chronic idiopathic constipation, evidenced
by the range of outcome measures utilised within the studies in-
cluded in this review. Due to differences between study popula-
tions, the heterogeneity of the different samples and large range of
different outcome measures, meta-analysis was not possible. What
is clear, however, is the increasing need to include patient reported
outcome measures as the pre-specified primary outcome measure
for assessment of the effectiveness of biofeedback.
The outcome measures used in the included studies fall mainly
into three groups: (i) anorectal physiological outcome measures,
(ii) symptom diaries and symptom-based outcome scores or ques-
tionnaires and (iii) patient reported global satisfaction with treat-
ment. Anorectal physiological outcome measures include anorec-
tal manometric recordings or EMG recordings of pressure profiles
within the anal canal (e.g. resting tone, squeeze pressure and re-
sponse to straining) and were also used as a primary outcome mea-
sure in early non-randomised biofeedback studies (Lestar 1991;
Fleshman 1992). Attempts have been made to identify anorectal
physiological tests that are predictive of response to biofeedback
and inability to expel a balloon and decreased (more acute) anorec-
tal angle were found to be associated with poor outcomes (Shin
2010). There is little clinical consensus about the appropriateness
of many methods for assessing anorectal dysfunction and consti-
pation and the significance of normal and abnormal findings re-
mains unclear (Azpiroz 2002). Many abnormal results are found in
asymptomatic subjects (Azpiroz 2002). Anorectal physiology has
therefore been criticised as an outcome measure, as these parame-
ters do not always reflect symptomatic improvement (Koutsoman-
is 1994; Rhee 2000), and abnormalities of anorectal function have
been reported in healthy non-constipated subjects (Rieger 1997;
Rao 1998). Given that anorectal measures do not always link to
patients’ perceptions of improvement (Papachrysostomou 1994),
they should not be used as a primary outcome measure to assess
the success of biofeedback therapy. It is also likely that where such
measures have been used, findings may not be comparable be-
tween different studies because of variations in test equipment and
biofeedback techniques.
Using symptom based outcome measures without patient subjec-
tive reports of improvement can lead to differences of opinion be-
tween patients and researchers. This was demonstrated in a non-
randomised study of biofeedback where a patient considered the
treatment to be a failure in spite of an increase in the number of
unassisted bowel movements and cessation of laxative use (Wexn-
er 1992). Perceptions of improvement can be influenced by pa-
tients’ expectations of outcome and may well be linked to per-
ceived quality of life. However, only two of the included studies
assessed the impact of biofeedback on quality of life (Heymen
2007; Lehur 2008). Stool frequency has been commonly used as an
outcome measure, either individually or with other symptoms. It
has been shown that 40% of constipated patients in one non-ran-
domised study passed pellets more than once a day before biofeed-
back and after the intervention bowel frequency was actually re-
duced (Rao 1998). If such patients were included in a study assess-
ing biofeedback therapy, their frequencies may skew the mean da-
ta. Thus bowel frequency may not be the most suitable outcome
measure to assess the efficacy of biofeedback. The US FDA has iden-
tified complete spontaneous bowel movements (CSBM) as the pre-
ferred patient-reported outcome, recommending this as the pri-
mary end-point for registry trials of constipation treatments. Only
one study in this review utilized this outcome (Rao 2007), although
many included studies pre-dated this recommendation. There is no
international consensus on the use of CSBM as the primary end-
point and this is not a requirement outside of the USA.
Rao 2007 investigated the effectiveness of manometry biofeedback
compared to a sham treatment and found that patients who re-
ceived biofeedback had a statistically significant increase in the
number of 'complete spontaneous bowel movements' per week
compared to baseline and sham biofeedback. However, the sham
intervention described by the authors as, "intermittent balloon dis-
tensions were performed with the rectal probe to promote aware-
ness for stooling and match the sensory conditioning provided un-
der biofeedback" (Rao 2007), might be considered a form of balloon
sensory training, which has been incorporated in some biofeed-
back programmes. For example, Heymen 1999 included balloon
sensory training in which "patients with constipation who had high
sensory thresholds (i.e. poor recognition of the urge cue) were
trained to perceive decreasing volumes of distention" (Heymen
1999). Similarly, this technique was reported in a non-randomised
study that was excluded from this review (Chiotakaku-Faliakou
1998). Specialist centres in the UK use balloon sensory training in
conjunction with EMG biofeedback as a component of therapy. The
Rao 2007 study may be better described as a trial of one method of
biofeedback versus another. Further research comparing EMG and
other methods of biofeedback to a credible sham treatment is re-
quired.
Ten studies compared biofeedback with other medical or surgi-
cal treatment. These treatments included 'standard care' and laxa-
tives, botulinum toxin-A injection, diazepam and surgical interven-
tions, but findings need to be interpreted with caution due to the
high risk of bias in most studies. Some of these interventions in-
cluding botulinum toxin-A injection, diazepam and surgery are not
widely used, although they were considered to be 'conventional' by
the reporting authors.
Rao 2007 compared manometry biofeedback to standard therapy
consisting of diet, exercise and laxatives. The authors found a sta-
tistically significant increase in the number of complete sponta-
neous bowel movements per week at three months in the biofeed-
back group compared to the standard care group. Chiarioni 2006
reported EMG biofeedback to be significantly superior to conven-
tional treatment with laxatives and dietary and lifestyle advice. The
results of these studies should be interpreted with caution due to
the small numbers of patients enrolled and a high risk of bias due
to lack of blinding.
Heymen 2007 compared the effectiveness of EMG biofeedback with
oral diazepam or a placebo tablet. Clinical improvement at three
months was significantly better in the biofeedback group com-
pared to both diazepam (P < 0.001) and placebo tablets (P = 0.017).
The authors asserted that diazepam was selected as a control as
this intervention was commonly used in clinical practice. However,
this intervention has not been reported in any other study, is not
widely used and may be an idiosyncratic practice within the clinical
setting in which the study was undertaken.
Farid 2009 compared the effectiveness of sensory training biofeed-
back to botulinum toxin-A injections into the external anal sphinc-
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ter and puborectalis muscles. Botulinum toxin-A injection may
have short term benefits over biofeedback, but the benefit does
not last. Botulinum toxin-A was found to perform significantly bet-
ter than biofeedback at one month but there was no statistically
significant difference at one year. The authors concluded that the
botulinum toxin-A injections were significantly more effective than
biofeedback initially, in contrast to You 2001, but that this effica-
cy was not maintained at one year in most patients. These results
should be interpreted with caution due to a high risk of selection
bias due to patient preference and lack of blinding and the small
number of patients enrolled (Farid 2009). While botulinum toxin-A
injections may provide more immediate relief through paralysis of
the pelvic floor musculature, the effects are only temporary and
deteriorate with time so that injections need to be repeated every
three months or so. The authors of this study used only a single in-
jection and treatment was not repeated, so it is unclear if repeat-
ed efficacy would be achieved with repeated injections compared
with biofeedback. The effect of biofeedback was less immediate,
but may be maintained over time without the need for further train-
ing beyond the initial intervention. This same group (Faried 2010),
also reported a comparison of biofeedback with both botulinum
toxin-A injections and surgery (i.e. bilateral open partial division of
puborectalis). Recruitment was slow and there was a risk of selec-
tion bias due to patient preference. Although there was a statisti-
cally significant difference in constipation score at one year favour-
ing surgery over biofeedback this difference is not likely to have any
clinical significance. Farid 2009 reported screening consecutive pa-
tients referred to the same institution over the same time period
as the Faried 2010 study, with identical demographics reported for
both studies. This suggests that the two manuscripts report the re-
sults of the same study, however, with major inconsistencies in re-
porting details. This is a major concern. Attempts to obtain clari-
fication from the authors on this point were unsuccessful and we
could find no published comments from other specialist clinicians
on these studies.
You 2001 reported no difference in clinical improvement between
biofeedback and surgery (i.e. mycomectomy), whereas two studies
reported that surgery (i.e. bilateral open partial division of puborec-
talis or stapled transanal rectal resection) was superior to biofeed-
back for clinical improvement (Lehur 2008; Faried 2010) and im-
provement in constipation score (Faried 2010) or obstructed defe-
cation score (Lehur 2008) at one year follow-up. However, adverse
events were much more common in the surgical groups than the
biofeedback groups. The results of these studies need to be inter-
preted with caution due to a high risk of bias in these studies (i.e. se-
lection bias and lack of blinding) and the small numbers of patients
enrolled. Further research is required. Even if surgical interventions
are shown to be superior to biofeedback, they are invasive, require
a general anaesthetic and are clearly not without risk. It is therefore
important that patient preference is considered when deciding on
treatment options for individual patients.
There is a lack of evidence as to whether any one method of
biofeedback is more effective than any other method of biofeed-
back. Clinicians often take a pragmatic approach and use the meth-
ods available locally. Some poor quality studies included in this
review suggest that EMG biofeedback could be superior to oth-
er methods including balloon sensory biofeedback (Bleijenberg
1994; Koutsomanis 1995), and manometry (Glia 1997). However,
the superiority of EMG biofeedback was not statistically signifi-
cant in these studies and there was a lack of consistency in re-
sults, which could be due to the heterogeneity of samples, differ-
ent methods and biofeedback techniques employed and different
outcome measures used (Shin 2010). This echoes the findings of
a previous systematic review (Koh 2008). Differences in diagnos-
tic methods, selection criteria, type of treatment (including type
of biofeedback, number of sessions and duration of training) may
go some way to explaining the variation in results from the litera-
ture. Some investigators have shown that biofeedback can be suc-
cessful without the use of electronic feedback (Koutsomanis 1995).
Most, however, insist that biofeedback must incorporate the use of
some form of electronic feedback. The funding arrangements for
biofeedback in some healthcare systems are such that only treat-
ments with biofeedback that incorporates EMG are paid for by in-
surers. Investigators possibly have a vested interest in proving that
this form of biofeedback is effective. It is clear that there is no con-
sensus or standardised regimen for administering biofeedback and
as no two intervention protocols used in the 17 studies were the
same, meta-analysis was not possible.
The results of this review show that there is insufficient evidence
from high quality randomised controlled trials to support the effec-
tiveness of biofeedback for the management of chronic idiopathic
constipation. Although the studies are not ideally designed, some
studies enrolled patients who had failed multiple treatments and
had severe symptoms (Chiarioni 2006; Rao 2007). Biofeedback may
be appropriate for these patients, although the quality of the evi-
dence is limited. The methodological quality and quality of report-
ing of randomised controlled trials of biofeedback for idiopathic
constipation has improved over time, but there is still a lack of high
quality trials without risk of bias to support this intervention and
on which to base recommendations. As the quality of trial methods
and reporting has improved over time, there is now some evidence
that the effect of biofeedback for constipation is specific and more
than simply a placebo response, but further studies with low risk of
bias are required to confirm these findings.
Summary of main results
We found low or very low quality evidence from randomised con-
trolled trials to support the effectiveness of biofeedback for the
management of people with chronic idiopathic constipation and
dyssynergic defecation. However, the majority of trials are of poor
methodological quality and subject to bias.
Overall completeness and applicability of evidence
There was a wide variation among trial reports in terms of charac-
teristics of participants, characteristics of interventions, choice of
outcome measures, duration of treatment and length of follow-up.
Most of the trials were small and probably of insufficient power to
detect any differences between intervention groups. The outcome
measures used were often insufficiently reported to enable further
statistical analyses. Length of follow-up was inadequate in many of
the trials. The way in which data were reported in many of the tri-
als (e.g. by not reporting measures of variance) made a quantitative
synthesis of results (meta-analysis) impossible.
Quality of the evidence
The results of all of the included studies need to be interpreted with
caution as GRADE analyses rated the overall quality of the evidence
for the primary outcomes (i.e. clinical or global improvement as de-
fined by the studies) as very low (See Summary of findings for the
main comparison; Summary of findings 2; Summary of findings 3),
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or low (See Summary of findings 4; Summary of findings 5; Summa-
ry of findings 6; Summary of findings 7) due to high risk of bias (i.e.
open label studies, self-selection bias, incomplete outcome data,
and baseline imbalance) and imprecision (i.e. sparse data).
Most studies were of poor methodological quality with a high risk
of bias and reporting in many of the studies did not conform to the
CONSORT statement for the quality of methodological reporting
of RCTs (Moher 2001). In spite of the lack of high quality evidence,
there is expert consensus that biofeedback is the gold standard
medical management for patients with chronic idiopathic consti-
pation and dyssynergic defecation (Whitehead 2010).
Potential biases in the review process
We attempted to reduce bias in the review process. A comprehen-
sive literature search was performed to identify all applicable stud-
ies. Two review authors independently assessed studies for inclu-
sion, extracted data and assessed study quality.
Agreements and disagreements with other studies or
reviews
While several literature reviews of the effectiveness of biofeedback
have been published (Enck 1993; Enck 1996; Bassotti 1997; Schiller
2001; Coulter 2002; Heymen 2003; Jorge 2003; Bassotti 2004; Pals-
son 2004; Chiarelli 2008; Chiarioni 2008; Koh 2008; Rao 2008; Zhou
2008; Enck 2009), and often by the same groups of authors, on-
ly four include a systematic approach to searching the literature
for randomised controlled trials and are considered here (Chiarelli
2008; Koh 2008; Zhou 2008; Enck 2009). Of these systematic reviews
only three include any meta-analysis of RCTs (Koh 2008; Zhou 2008;
Enck 2009), and the work of Zhou and colleagues is only available
as an abstract (Zhou 2008). All four of these reviews had method-
ological limitations.
Zhou 2008 undertook a meta-analysis of eight trials involving 488
patients and found that biofeedback was an effective method for
the management of chronic idiopathic constipation compared to
laxatives and non-biofeedback therapy. They concluded that EMG
biofeedback was as effective as manometry biofeedback, but the
methods for the review were not fully reported and inclusion and
exclusion criteria were not described.
Chiarelli 2008 conducted a somewhat limited review. While a sys-
tematic process was followed the review was limited by only includ-
ing studies published in English and failing to search the Cochrane
CENTRAL database of randomised controlled trials, conference ab-
stracts or other trial registers. The date the literature search was
conducted was not reported, but the most recent study included
was published in 2006. The search strategy was not comprehen-
sive. Chiarelli 2008 did not include studies that were identified by
the search strategy for this review (You 2001; Chang 2003; Hu 2006;
Jung 2007). Chiarelli 2008 also incorrectly included narrative re-
views that were not 'systematic reviews' and these reviews were
excluded from the current review.
Koh 2008 conducted the most robust review, searching most of the
available relevant electronic databases and placing no language
limits on the randomised controlled studies they included. Howev-
er, their search strategy was not comprehensive enough and they
failed to identify several studies that were published prior to their
review that were included in this review (You 2001; Chang 2003; Hu
2006; Jung 2007). The seven studies included by the authors were
correctly identified as being heterogeneous and yet these studies
were combined in a meta-analysis. This was not appropriate as
meta-analysis should only be conducted for homogeneous studies
that are investigating the same population of people, the same in-
tervention and the same outcome measures and clearly this was
not the case.
Enck 2009 conducted a limited review, searching only PubMed and
no other databases. Their review was also limited to English lan-
guage papers only and searched for papers published between
1980 and 2008. As with the other reviews, four RCTs of biofeedback
for chronic idiopathic constipation were missed by the search (You
2001; Chang 2003; Hu 2006; Jung 2007), and more interestingly the
authors included a study published in 2009 which was beyond the
date limits of their search (Farid 2009). This brings into question
whether the search strategy and limits of the search were strictly
applied by the authors. As with the Koh 2008 review a meta-analy-
sis of heterogeneous studies was undertaken. This meta-analysis
included only four RCTs of biofeedback compared to 'non-biofeed-
back' modalities and reported an odds ratio of 3.657 (95% CI 2.127
to 6.290) in favour of biofeedback. As these confidence intervals
were narrow and did not cross the line of no effect, the authors con-
cluded that biofeedback was significantly superior to other thera-
pies (P < 0.0001). However, this pooled analysis was not appropri-
ate. The comparator groups for each of the four studies were dif-
ferent and included laxatives (Chiarioni 2006), an oral placebo for
diazepam (Heymen 2007), sham biofeedback (Rao 2007), and bot-
ulinum toxin-A injections (Farid 2009). All four studies included in
this meta-analysis were rated as high risk of bias for lack of blinding
(Chiarioni 2006; Heymen 2007; Rao 2007; Farid 2009), possible self-
selection bias (Heymen 2007), and participant groups that were not
comparable at baseline (Rao 2007).
The consistent findings from these reviews were that biofeedback
was superior to control interventions and that the methodological
quality of trials of biofeedback for chronic idiopathic constipation
was generally poor and that further research was required. These
findings are broadly consistent with the outcomes of this review.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Currently there is insufficient evidence to allow any firm conclu-
sions regarding the efficacy and safety of biofeedback for the man-
agement of people with chronic constipation. We found low or very
low quality evidence from single studies to support the effective-
ness of biofeedback for the management of people with chronic
constipation and dyssynergic defecation. However, the majority of
trials are of poor methodological quality and subject to bias. Most
studies investigated biofeedback in patients with dyssynergic defe-
cation only and excluded those with isolated slow transit consti-
pation. We found some evidence that suggests biofeedback may
be effective for the management of chronic idiopathic constipation
and superior to oral diazepam, sham biofeedback and laxatives.
Some surgical procedures were reported to be superior to biofeed-
back although patients who had surgery had a high risk of adverse
events (Lehur 2008; Faried 2010). Conflicting results were found re-
garding the comparative effectiveness of biofeedback and botu-
linum toxin-A. One small study suggested that botulinum toxin-A
injection may have short term benefits over biofeedback, but the
benefit did not last at one year follow-up. We found very poor evi-
dence that any one method of biofeedback was superior to any oth-
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er method of biofeedback. There were no reports of adverse events
from biofeedback in any of the studies and it is fairly unlikely that
this intervention will cause significant harm.
Implications for research
There is a need for well-designed randomised controlled trials with
adequate sample sizes, validated outcome measures (especial-
ly patient reported outcome measures) and long-term follow-up.
However, it is unclear which patient reported outcome measures
and physiological end-points are most important. While the con-
cept of complete spontaneous bowel movements has gained popu-
larity, it is not clear that this is the most important outcome from all
patients' perspectives. Further work to define patient reported out-
come measures, including symptom and disease specific quality of
life outcomes that reflect those symptoms that are most bother-
some to patients is required. Patient satisfaction with bowel func-
tion and treatment may not always correlate with an increase in
the number of complete spontaneous bowel movements or other
physiological end points, such as gut transit or expulsion of a wa-
ter-filled balloon. Further work to define an appropriate sham for
biofeedback is also required.
There are now other treatments available for the management
of chronic idiopathic constipation, such as prokinetic agents (e.g.
prucalopride) and modes of electrical stimulation, which were not
available when many of the included studies were conducted.
Future studies should compare biofeedback with these interven-
tions and any other newer pharmacological, surgical or behav-
ioural treatments that are developed. Biofeedback should also be
compared to established conventional treatments for constipa-
tion. Most studies were conducted within secondary or tertiary care
populations and there is a need for well-designed trials in primary
care settings.
In addition there is a need for studies assessing the effectiveness
of the different components or methods of 'biofeedback', including
the information, education and counselling given to patients, exer-
cises, balloon sensory training and EMG or manometry feedback of
sphincter and pelvic floor function. Economic outcomes should al-
so be assessed in future studies. Studies that explore the effective-
ness of biofeedback for patients with pelvic floor dyssynergia (with
or without slow gut transit) and patients with slow gut transit with-
out evidence of dyssynergic defecation are required.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Study design: randomised controlled trial
Total study duration: Mean follow-up 14 months (SD 8.9; range 3 to 28 months) for EMG biofeedback
and 9 months (SD 7.0; range 3 to 26 months) for comparison group
Participants 21 patients, all with pelvic floor dyssynergia and constipation
N = 11 electromyograph (EMG) biofeedback (8 female, 3 male) (mean age 35 years, range 20 to 50
years); duration of symptoms (mean 8 years, range 2 to 11years)
N = 10 balloon biofeedback (8 female, 2 male) - 1 drop out (mean age 40 years (range 28 to 47 years));
duration of symptoms (mean 7.5 years, range 2 to 15 years)
No difference between groups at pre-test
Interventions No laxatives allowed
Weekly outpatient sessions for 8 weeks
Intervention group:
Phase 1: EMG biofeedback using anal-plug electrode and digital display
Phase 2: simulated defecation of oatmeal porridge
Phase 3: toilet instructions - to strain a maximum of 5 times on the toilet after each meal and patient to
decide whether 'straining' was correct or not
Comparison group:
Phase 1: Balloon biofeedback using balloon catheter inflated with 20 mL air inserted 8 cm into rectum,
patient to pull balloon out over 10 seconds without straining
Phase 2 and 3 same as EMG biofeedback
Outcomes EMG quality score (based on depth and amplitude of EMG signal from 0 to 100: 0 = no relaxation during
straining, 100 = maximal relaxation)
Patient symptom diary (recorded 4 times daily): frequency, difficult evacuation, incomplete evacua-
tion, hard stools, abdominal pain
Constipation score (calculated from symptom diary)
VAS (0 to 200: 100 = unchanged) of subjective rating of change
SCL-90 - validated psychopathology symptom checklist
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Bleijenberg 1994 
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Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Low attrition (one participant only)
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias Low risk The study appears to be free of other sources of bias
Bleijenberg 1994  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: 10 to 12 days - no long-term follow-up beyond end of treatment
Participants 22 patients selected from 130 consecutive referrals who met Rome II criteria for functional constipation
and were thought to have 'impaired rectal sensation' defined as rectal sensory threshold volume for
desire to defecate of > 90 mL
Electrical stimulation: n = 12 (5 male, 7 female) (Age - mean 41 years (range 18 to 71 years)
Electromyograph (EMG) biofeedback: n = 10 (6 male 4 female) (Age - mean 53 years (range 28 to 74
years)
Duration of symptoms not reported
Baseline comparability- reported 'no significant difference', but no P values were reported
Interventions Intervention group:
Electrical stimulation using anal plug with pulse generator introduced into the anal canal
'Variant stimulation' parameters scheduled individually within pre-specified range
Performed for 20 minutes daily for 10 to 12 sessions
Comparison group:
EMG biofeedback with visual changes in pressure activity displayed on monitor
10 to 14 sessions lasting 60 to 90 minutes (frequency not reported)
Outcomes Symptom questionnaire (bowel frequency and urge, satisfaction with bowel habit, straining, sensation
of incomplete evacuation, anal obstruction scored on VAS)
Anorectal manometry immediately before and after each treatment
Rectal sensation measured using balloon distention
Notes  
Risk of bias
Chang 2003 
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Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No attrition
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias Unclear risk Disproportionate number of male participants compared with usual biofeed-
back population
Chang 2003  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: 12 months for both groups, 24 months for biofeedback group only
Participants 109 patients with severe constipation (Rome II criteria) for > 12 months, unresponsive to standard
treatment or 30 day trial of fibre
All with paradoxical contraction or non-relaxing pelvic floor on EMG and inability to defecate 50 mL wa-
ter-filled balloon
Excluded patients with slow transit
Biofeedback n = 54 (3 male, 51 female) (Age - mean 33.3 years (SE +/- 1.5 years)
Controls n = 55 (2 male, 54 female) (Age - mean 35.1 years (SE +/- 1.4 years)
The authors reported groups to be similar at baseline, but no statistical analysis of comparability was
reported
Interventions Intervention group:
Biofeedback: 5 weekly 30 minute training sessions
EMG biofeedback with contraction and relaxation of pelvic floor displayed on monitor
Practice defecation of simulated stool (50 mL water-filled balloon) while traction applied
Comparison group:
Laxatives (polyethylene glycol [PEG] 14.6 g/day) plus education
Five 30 minute counselling sessions: avoiding unnecessary straining, defecation posture, routine, phys-
iology of constipation, adverse effects of PEG discussed
Chiarioni 2006 
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Outcomes Patient response to the question "how would you grade your symptom improvement: worse (0), no im-
provement (1), mild (2), fair (3) or major improvement (4)" (primary outcome)
Bowel diary of stool frequency, laxative use (other than PEG), straining, sense of incomplete evacu-
ation, feeling of blocked defecation (kept for 30 days prior to follow-up visits following telephone re-
minder)
Anorectal manometry (anal canal pressure)
Surface intra-anal EMG to measure responses to attempted defecation
Ability to defecate  a 50 ml water-filled balloon (simulated stool)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Shuffled sealed opaque envelopes
Allocation concealment
(selection bias)
Low risk Adequate concealment: sealed opaque envelopes
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Intent-to-treat analysis
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias Low risk The study appears to be free of other sources of bias
Chiarioni 2006  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: 1 year
Participants 48 patients - all met Rome II criteria for functional constipation and unresponsive to laxatives or ene-
mas
All patients had anismus (non-relaxing anal sphincter) based on transit time, manometry, balloon ex-
pulsion test, defecography and EMG activity of external anal sphincter
Biofeedback n = 24 (8 male: 16 female) mean age 39.6 years (range 20 to 69 years), symptom duration
4.8 years (range 1 to 10 years)
Botulinum toxin-A n = 24 (7 male : 17 female) mean age 34.7 years (range 20 to 63), symptom duration
5.9 years (range 2 to 12 years)
Baseline comparability between groups was not reported
Farid 2009 
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Interventions Intervention group:
Biofeedback twice weekly for 1 month as outpatient.
Explained normal bowel and anal physiology
Sensory training biofeedback - 'pressure-based' using balloon expulsion
Comparison group:
Botulinum toxin-A injected (Dysport 100 u dissolved in saline (0.5 ml) single injection via insulin sy-
ringe) into leQ and right sides of the puborectalis and external anal sphincters with the patient in leQ
lateral position
No anaesthesia was necessary
Outcomes Improvement in bowel symptoms: "clinical improvement or success… Patients who returned to nor-
mal with regard to their bowel habits”
PR assessment of relaxation of puborectalis
Symptom questionnaire 1 month post-treatment and at 1 year (straining, anorectal pain, incomplete
evacuation, anal digitation and enema use) assessed using visual analogue scale
At 1 month: anorectal manometry, balloon expulsion test, defecography, EMG examination of anal
sphincter
At 1 year patients asked: “Are you satisfied with the result of procedure performed to you” [sic]
Notes It is noted that the authors report screening consecutive patients referred to the same institution over
the same time period (Colorectal Surgery Unit of Mansoura University Hospital, Mansoura, Egypt), with
identical demographics, for both this study (biofeedback and botulinum toxin-A arms) and for Faried
2010, suggesting that the two papers report the same study, however with major inconsistencies in re-
porting details, this is a major concern
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Low risk Sealed opaque envelopes
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Attrition reported and included in intent-to-treat analysis
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias High risk See comments in table above
Farid 2009  (Continued)
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Methods Study design: randomised controlled trial
Total study duration: 1 year
Participants 60 patients seen during recruitment period (> 3 years) met Rome II criteria for functional constipation
and unresponsive to laxatives
Anismus diagnosed as non-relaxing external anal sphincter, inability to expel water-filled balloon, non-
relaxing puborectalis, prolonged evacuation time
17 male, 43 female
Mean age 37.53 years (range 20 to 69 years)
No difference between groups at baseline
NB: demographic data for patients in two groups of this study are identical to the patients in Farid 2009
Interventions Intervention group:
Biofeedback (n = 20)
Two times per week for one month (8 sessions), expert therapist
Each session 30 minutes as out-patient
Explanation of pelvic floor and own test results
Pressure-based biofeedback learning to expel 50 mL balloon and push down with abdominal muscles
using 'trial and error'
Continued periodic supervision for 6 months if successful
Comparison groups:
1.Botulinum toxin (BTX-A) (n = 20) into  leQ and right sides of puborectalis and EAS as outpatient
2.Bilateral open partial division of puborectalis (n = 20) under GA
Outcomes Primary end point - 'improvement in bowel habits' using symptom questionnaire (unspecified - possi-
bly Cleveland Clinic Score) at 1 month
Success defined as bowel habits that 'returned to normal'
Secondary endpoints: complications, satisfaction using visual analogue scale (change of at least 2 out
of 10 score) post-operative incontinence, anorectal manometry balloon expulsion test, defecography
and EMG of anal sphincter
Notes It is noted that the authors report screening consecutive patients referred to the same unit over the
same time period, with identical demographics, for both this study (biofeedback and botulinum toxin-A
arms) and for Farid 2009, suggesting that the two papers report the same study, however with major in-
consistencies in reporting details
This is a major concern
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation sequence
Faried 2010 
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Allocation concealment
(selection bias)
Low risk Sealed opaque envelopes
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No attrition
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias High risk See comments in table above
Faried 2010  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: six month follow-up following five week intervention
Participants 26 consecutive patients with functional constipation - based on Rome I criteria - organic lesions exclud-
ed
Proportion of females or males not reported. Age - mean 55 years (range 28 to 78 years); duration of
symptoms - mean 11 years (range 1 to 35 years)
10 patients had rectocele, 1 had enterocele, 11 had intussusception and 4 had rectal prolapse
Baseline comparability between groups not reported
Interventions Intervention group:
Manometry Biofeedback 1 to 2 sessions per week for maximum of 10 sessions
Pressure-based training using four-lumen catheter - patients were allowed to view manometric record-
ings of pressure and encouraged to relax anal sphincter during balloon expulsion
Comparison group:
EMG biofeedback using bilateral surface electrodes, same frequency as manometry
Outcomes Balloon expulsion test of 60 mL water filled balloon.
Whole gut transit
Anorectal manometry and EMG
Bowel symptom diary daily for 1 week
Global rating of treatment effect: worse or unaltered or better
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Glia 1997 
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Random sequence genera-
tion (selection bias)
Low risk Computer randomised sequence generation
Allocation concealment
(selection bias)
Low risk Sealed opaque envelopes
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
High risk High attrition (six participants from 26, but three from each group) and no in-
tention-to-treat analysis
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias Unclear risk Recruitment bias and power unclear
Glia 1997  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: 12 weeks - no long-term follow-up
Participants 21 outpatients with pelvic floor dyssynergia, failed lifestyle modification and other medical interven-
tions
Confirmed pelvic floor dyssynergia on anorectal manometry, balloon expulsion and defecography
14 female:1 male. Mean age (SD) 50.1 years (16.8 years)
Duration of symptoms not reported
n = 10 randomised to biofeedback; n = 11 randomised to control
Gender split unequal between groups at baseline
Interventions Intervention group:
Anorectal biofeedback by registered nurse
Six 1 hour sessions (alternate weeks) - 20 minutes EMG biofeedback (rectal probe) plus coaching for re-
laxation of pelvic floor muscles
Practice pelvic floor exercises between sessions
Comparison group:
Muscle relaxation of trapezius or temporalis with feedback from registered nurse
Six 1 hour sessions (alternate weeks) - EMG with surface electrodes on either site plus coaching for re-
laxation of the right and leQ trapezius or right and leQ temporalis plus breathing technique
Practice relaxation and breathing technique between sessions
Outcomes Constipation severity instrument (3 subscales: obstructive defecation, colonic inertia, pain)
Irritable bowel syndrome quality of life scale (IBS-QOL)
Hart 2012 
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SF-36
History of childhood sexual or physical abuse using Trauma History Questionnaire (24-item scale for
traumatic events in 3 areas: crime-related events, general disaster and trauma, unwanted physical and
sexual experiences)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer generated randomisation sequence
Allocation concealment
(selection bias)
Unclear risk Reported allocation concealed until randomised, although method unclear
Blinding (performance
bias and detection bias) 
All outcomes
High risk Participants and therapists not blinded: assessor blinding unclear
Incomplete outcome data
(attrition bias) 
All outcomes
High risk 4 dropped out from biofeedback group, 2 from control group: total attrition n =
6 from 21
Selective reporting (re-
porting bias)
Low risk Registered prospectively on clinical trials registry
Other bias Low risk The study appears to be free of other sources of bias
Hart 2012  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: no follow-up beyond end of treatment
Participants 36 patients referred to tertiary centre with pelvic floor dyssynergia, who required laxatives, enemas,
digitation or combination to achieve bowel movement
(26 female, 10 male) gender split between groups was not reported
Age - mean 61 years (range 18 to 82 years); duration of symptoms not reported
Baseline comparability not reported
Interventions Randomised to four groups
All patients in intervention and comparison groups also educated as to normal bowel function, pos-
ture, not to prolong defecation attempts beyond 10 to 15 minutes, not to strain and to schedule bowel
movements after meals or exercise
Intervention group:
Group 1: Weekly one hour  EMG biofeedback - use of intra-anal sensor with EMG display of muscle activ-
ity
Comparison groups:
Heymen 1999 
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Group 2. EMG biofeedback plus balloon distention sensory training (using flexible manometry catheter
with balloon attached and inflated up to 140 mL)
3. EMG biofeedback plus home trainer EMG biofeedback unit
4. EMG biofeedback plus balloon distention sensory training plus home trainer EMG biofeedback unit
Outcomes Change in frequency of unassisted bowel movements (UBM) (meaning of UBM not defined)
Laxative use
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No attrition reported
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias High risk Primary outcome was assessed by unblinded therapist making contact with
patients by telephone
Heymen 1999  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: 12 months follow-up for those who reported adequate relief only
Participants 84 patients who met Rome II criteria for pelvic floor dyssynergia and chronic constipation, manometric,
EMG or defecographic evidence of non-relaxing pelvic floor, inadequate propulsive forces during defe-
cation on manometry
Evidence of incomplete evacuation
Excluded patients currently using diazepam or previous use of biofeedback
Still symptomatic following 4 week run in with education regarding diet, exercise, fluid intake, bowel
function and correct defecation technique
84 patients (85% female) randomised to biofeedback (n = 30) (mean age 51.4 years, symptom dura-
tion 14 years), diazepam (n = 30) (mean age 51.7 years, symptom duration 14.5 years), placebo (n = 24)
(mean age 46.1 years, symptom duration 19 years)
Heymen 2007 
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Interventions Intervention group:
Intensive education intervention plus EMG biofeedback to teach relaxation of pelvic floor during strain-
ing to defecate
Six x 50 minute biweekly sessions over 3 months using EMG anal plug and function of anal sphincters
displayed on monitor
Comparison group:
(1) Diazepam 5 mg orally one hour before attempted defecation
(2) Placebo in place of diazepam one hour before attempted defecation
Patients in both of these groups received the same intensive education as the intervention group but
no biofeedback
Outcomes Primary outcome: report of adequate relief of constipation at 3 months follow-up assessed by ques-
tion asked by the therapist during a telephone follow up interview: "compared to before you started
the study, have you experienced adequate relief of constipation?"
Secondary outcomes: Bowel symptoms - unassisted bowel movements, assisted bowel movements,
straining, incomplete evacuation
PAC-SYM
PAC-QOL
SF36
Anorectal manometry
EMG testing
Whole gut transit time
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Both the investigators and the patients knew whether the patients were as-
signed to biofeedback or to pills
Partial blinding between diazepam and placebo only
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Intent-to-treat analysis
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias High risk Possible self-selection bias among participants
Heymen 2007  (Continued)
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Methods Study design: randomised controlled trial
Total study duration: 12 weeks
Participants 60 patients who met Rome II criteria for chronic idiopathic constipation
Symptoms lasting 1 year or more
No organic pathology - ruled out via colonoscopy
Mean age 44
95% female
Randomised biofeedback (n = 30), control (n = 30)
Interventions All patients stopped laxatives in both groups
Intervention group:
Biofeedback - teaching of proper defecation posture, abdominal muscle and pelvic floor exercises,
'pressure' training and balloon expulsion training
Each session 30 to 60 minutes every two weeks for six sessions
Comparison group:
Lifestyle, dietary and general advice only
Timing of sessions as biofeedback 
Outcomes Symptom diary - daily bowel habits and use of rescue laxatives
Constipation symptom severity questionnaire - 5 point Likert scale
Notes abstract only - never published as full manuscript in peer reviewed literature
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Attrition not reported
Selective reporting (re-
porting bias)
Unclear risk All patients stopped laxatives in both groups
Other bias Unclear risk Full manuscript not published
Hu 2006 
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Methods Study design: randomised cross-over design
Total study duration: five weeks
No long-term follow-up beyond end of treatment
Participants 40 patients who met Rome II criteria for pelvic floor dyssynergia
Intervention group (n = 20) (21 to 77 years, Male/Female 8:12)
Comparison group (n = 20) (24 to 70 years, Male/Female 7:13)
Interventions Intervention group:
Electrical stimulation therapy (EST) for 2 weeks then Biofeedback for 5 weeks
EST performed for 24 minutes (EST parameters not reported) for twelve sessions using anal plug and
pulse generator
Comparison group:
Biofeedback (unspecified method) for 5 weeks then EST for 2 weeks
Outcomes Symptom assessment (subjective overall satisfaction, straining, incomplete evacuation, feeling of ob-
struction) rated from 0 to 10
Patient’s opinion about treatment (success/fail)
Anorectal manometry
Balloon expulsion
substance P expression within rectal mucosa
All above recorded before and after each treatment
Notes Abstract only - never published as a full manuscript in peer reviewed literature
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Not reported
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not reported
Selective reporting (re-
porting bias)
Unclear risk Drop outs not reported
Jung 2007 
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Other bias Unclear risk Not published as a full manuscript
Jung 2007  (Continued)
 
 
Methods Study design: Randomised controlled trial
Total study duration: 2 to 3 month follow-up
Participants 60 patients all unresponsive to standard treatment
Included both patients with pelvic floor dyssynergia (n = 47) and slow transit (n = 17)
30 biofeedback (24 female, 6 male) - 1 withdrew and lost to follow-up, age - mean 40 years (range 20 to
64 years), duration of symptoms 14 years (range 1 to 40 years)
30 muscle training (29 female, 1 male), age - mean 41 years (range 23 to 63 years), duration of symp-
toms 13 years (range 3 to 40 years)
Reported 'no major differences' between groups at baseline, but no statistical comparison presented
Interventions Intervention group
Visual biofeedback:
Muscle training: Patient taught to direct propulsive forces towards pelvis, while relaxing and protruding
lower abdomen to pass balloon filled with 50 mL air, when lying on leQ side, plus watched EMG trace on
a computer screen from surface electrodes placed on the skin over the external anal sphincter at the
anal margin.
Comparison group
Muscle training as for other group without visual display.
Outcomes Patient symptom diary (daily for 1 week)
Whole gut transit
Surface EMG
Simulated defecation (50 mL water filled balloon) - successful if balloon passed within 5 minutes
All outcomes were assessed at end of treatment and symptom diary only during 2 to 3 month follow-up
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Low risk Sealed opaque envelopes
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Koutsomanis 1995 
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Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Low attrition (only one participant from intervention group), but no intent-to-
treat analysis
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias Unclear risk Recruitment bias and power unclear
Koutsomanis 1995  (Continued)
 
 
Methods Study design: randomised controlled trial across nine European centres
Total study duration: 12 months
Participants 119 female patients with 'obstructive defecation syndrome score' >7 (score is the sum of individual
scores for 7 symptoms of outlet obstruction), all had confirmed rectocele on defecography, 'Adequate
(not defined) external sphincter function on examination
STARR group (n = 59) mean age (± SD) 56 years (± 9.2 years: range 34 to 80 years)
Biofeedback group (n = 60) mean age 56 years (± 14.3 years: range 24 to 78 years)
Interventions Intervention group:
Stapled transanal rectal resection (STARR) under general anaesthetic, with patient in lithotomy posi-
tion
Designed to achieve transanal full-thickness resection of the lower rectum
Used 2 times Ethicon Endo-surgery PPH01 kits per procedure
Same surgeon at each centre, all trained and had conducted 10 STARR procedures previously
Comparison group:
Biofeedback training two sessions per week for a planned minimum of 10 sessions, but not > 24 given
over 3 month period
Each session 1 hour of EMG based biofeedback - visual and acoustic feedback via perianal skin elec-
trodes of muscle relaxation during straining
Biofeedback 'standardised among different practitioners'
Outcomes Primary outcome: obstructed defecation score (ODS)
Defined a responder a priori as ≥ 50% reduction in ODS score at one year
Secondary outcomes:
PAC-QOL
Continence grading scale (interviewer-led questionnaire) (six questions rated 0-4)
Patient-reported success (self-administered questionnaire) (1-10 scale)
Anatomic correction of rectocele in surgery group only
Adverse events
Lehur 2008 
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Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Sequence generation not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
High risk High drop out (50%) from biofeedback group and not all included in inten-
tion-to-treat analysis
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias Low risk The study appears to be free of other sources of bias
Lehur 2008  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: follow-up 1 week following treatment completion (6 sessions)
Participants 65 out-patients with dyssynergic defecation (Rome III criteria): symptoms > 6 months
Failed to respond to diet and lifestyle modification, psyllium husk and daily exercise
49 women: 16 men
EMG Biofeedback group (n = 34) mean age (SD) 38 years (12 years)
Balloon-assisted training group (n = 31) mean age (SD) 36.8 years (10 years)
No significant differences between groups at baseline
Interventions Intervention group:
EMG biofeedback: trained to increase abdominal pressure and relax rectal muscles
Frequency of 6 training sessions not reported
Comparison group:
Balloon defecation training: asked to expel water-filled balloon
Frequency of six training sessions not reported
Outcomes Satisfaction (low, moderate or high)
Change in Rome III criteria
Pourmomeny 2010 
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Ability to expel a rectal balloon (volume and time)
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Alternate allocation
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk ITT analysis but did not report number of participants who completed or how
missing data were dealt with within ITT
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias Low risk The study appears to be free of other sources of bias
Pourmomeny 2010  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: 3 month and one year follow-up (one year follow-up reported in separate paper
(Rao 2010))
Participants 77 patients referred to tertiary centre for constipation and met Rome II criteria for functional constipa-
tion.
Evidence of pelvic floor dyssynergia on attempted defecation
77 patients (69 female, 8 male) randomised 24 to standard therapy, 28 to biofeedback, 25 to sham
biofeedback)
Age - mean 43 years (range 18 to 75 years)
Mean symptom duration 17 years
No difference in demographics between groups at baseline, but biofeedback group had 'significant-
ly lower defecation index' and 'relatively greater pelvic floor dysfunction' (Rao 2007, p.333) than other
groups at outset
Interventions Intervention group:
Manometry biofeedback: biweekly one hour sessions up to maximum of 6 over a three month period,
with visual display of anal sphincter pressures during simulated defecation
Also received standard advice: advice on bowel habit, diet, exercise, laxatives and fluid intake, postural
and diaphragmatic breathing techniques to improve pushing efforts
Comparison groups (2):
Rao 2007 
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Sham biofeedback: standard advice plus 6 biweekly I hour relaxation therapy sessions during a period
of 3 months
Manometry probe placed in rectum and practiced progressive muscle relaxation to audiotape for 20
minutes
Also received intermittent balloon distension using the rectal probe to match sensory conditioning
component of biofeedback
Outcomes Subjective primary outcome measure: number of complete spontaneous bowel movements (CSBM)
per week plus global satisfaction on visual analogue scale
Physiological primary outcome: dyssynergic pattern of defecation and balloon expulsion time
Secondary subjective outcome measures: symptom diary for 1 week: time and consistency of stool (us-
ing Bristol Stool Form Scale), straining, incomplete evacuation, digitation.
Secondary objective outcomes: anorectal manometry and colonic transit study
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated randomisation sequence
Allocation concealment
(selection bias)
Low risk Sealed opaque envelopes - adequate concealment
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk High attrition (n = 12 from 77), but performed intention-to-treat analysis at 3
months. From 52 patients randomised to biofeedback or standard care, data
from 20 are reported at one year
Selective reporting (re-
porting bias)
Low risk Registered on clinical trials registry
Other bias High risk The two groups were not equal at baseline as the biofeedback group had a sig-
nificantly lower defecation index and relatively greater pelvic floor dysfunction
than the sham group
Rao 2007  (Continued)
 
 
Methods Study design: Randomised controlled trial
Total study duration: follow-up for two months after end of treatment
Participants 30 participants with dyssynergic defecation unresponsive to diet or fibre, fulfil Rome III criteria
Paradoxical contraction of anal sphincter during defecation evident
Mean age 73.8 years (range 67 to 80 years)
11 male, 19 female
Simon 2009 
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Duration of symptoms mean 12.8 years (range 6 to 21 years)
No significant difference between groups for frequency of defecation per week (EMG biofeedback n =
15, control n = 15)
Interventions Intervention group:
EMG biofeedback - 8 sessions (x2 per week) over 1 month, each lasting 45 minutes
EMG during straining displayed via visual and auditory feedback, with patient lying in leQ lateral posi-
tion
Comparison group:
Eight 45 minute counselling sessions - covered behavioural mechanisms involved in defecation, diet,
positioning, avoid straining, routine time for defecation
Each session ended with EMG assessment during straining to defecate
Outcomes Self-report of bowel frequency, sensation of incomplete evacuation, evacuation difficulty and perianal
pain on defecation
Latter 3 symptoms rated on a scale (0 = no symptom, 5 = middle symptom, 10 = severe symptom)
EMG activity during rest, squeezing and straining to defecate - also used to calculate an 'anismus index'
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Reported no attrition
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias Low risk The study appears to be free of other sources of bias
Simon 2009  (Continued)
 
 
Methods Study design: randomised controlled trial
Total study duration: 1 year beyond end of treatment
Participants 80 patients with slow transit constipation
You 2001 
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Age ranged from 20 to 70 years
Duration of symptoms and baseline comparability not reported, male: female 4:1 (exact numbers not
reported - calculated to be 64 female, 16 male)
Distribution of characteristics not reported (20 patients in each of control groups, 40 in biofeedback
group)
Interventions Intervention group:
Biofeedback using device with anal probe - unclear if this was an EMG or manometry device plus pelvic
floor exercises, balloon training
Daily intervention for 14 days - not clear if as in-patient or outpatient
Comparison group:
(1) botulinum toxin-A injection to external anal sphincter and puborectalis
(2) posterior myomectomy of internal anal sphincter and puborectalis
Outcomes Defecation satisfaction level
Frequency of bowel movements
Transit time
Balloon expulsion
Anorectal physiology and EMG of anal sphincters and puborectalis
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Not reported
Allocation concealment
(selection bias)
Unclear risk Not reported
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not blinded
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk No attrition
Selective reporting (re-
porting bias)
Unclear risk Not registered on a clinical trials registry
Other bias Low risk The study appears to be free of other sources of bias
You 2001  (Continued)
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Study Reason for exclusion
Battaglia 2004 Non-randomised study
Binnie 1992 Non-randomised study
Chiarioni 2005 Non-randomised study
Chiarioni 2007 Letter - not a study
Chiarioni 2010 RCT of biofeedback for anal pain, not chronic idiopathic constipation
Chiotakakou-Faliakou 1998 Non-randomised study
Dallianas 2000 Non-randomised study
Emmanuel 2001 Non-randomised study
Enck 2009 Meta-analysis. Not an RCT
Ferrara 2001 Non-randomised study
Horton 2008 Contacted author
Trial abandoned due to poor recruitment
Keck 1994 Non-randomised study
Lin 2005 Non-randomised study
Included healthy controls
NCT00564707 Trial of biofeedback for anal pain, not constipation
Park 2003 Non-randomised study
Post-hoc analysis of responders and non-responders to biofeedback
Patankar 1997 Non-randomised study
Roy 2000 Non-randomised study
Siproudhis 1995 Non-randomised study
Wiesel 2001 Non-randomised study
Yang 2004 Non-randomised study
 
Characteristics of studies awaiting assessment [ordered by study ID]
 
Methods Unobtainable
Participants Unobtainable
Singles 1990 
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Interventions Unobtainable
Outcomes Unobtainable
Notes Unpublished thesis
Singles 1990  (Continued)
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Rectal Sensory Training - a randomized controlled study of two techniques
Methods Randomised, open label, parallel assignment trial comparing two techniques for rectal hyposensi-
tivity and constipation
Participants Patients categorised as having dyssynergic defecation or slow transit constipation or normal tran-
sit constipation
Interventions Intervention: syringe-assisted sensory conditioning (biofeedback)
Comparison: barostat assisted sensory conditioning
Outcomes Primary outcome - rectal sensory thresholds
Secondary outcome - satisfaction with bowel function based on visual analogue scale (VAS)
Starting date March 2004
Contact information Satish SC Rao, MD satish-rao@uiowa.edu
Notes Expected completion June 2012, but not yet published
NCT00982839 
 
 
Trial name or title Multicentre randomized controlled trial to compare the outcome of conservative triple target treat-
ment with EMG-biofeedback for chronic constipation (3T-CO)
Methods Parallel group randomised multicentre study with blinded observers
Participants 140 Patients > 18 years with chronic constipation (Rome II criteria)
Interventions Intervention:
Stimulation with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 KHz -
combination of EMG-biofeeback plus EMG-triggered AM-MF stimulation, carried out at home, with
an alternating combination in the morning and EMG-triggered stimulation in the evening for 20
minute periods.
Comparison:
EMG-biofeedback alone, carried out at home, standing, mornings and evenings for 20 minute peri-
ods.
Outcomes Primary outcome - Altomare ODS score in its validated form after 3 and 12 months, compared to
baseline
NCT01672216 
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Secondary outcomes -
• Constipation Severity Instrument• modified Wexner Incontinence Score• PAC-QOL• Hinton test• Cleveland Clinic Incontinence Score• Adapted Vaizey Score• International Consultation on Incontinence Questionnaire Short Form (ICIQ-SF)
Starting date August 2012
Contact information Dr T Schwander, University of Giessen, Dept of General Surgery, Giessen, Hessen, Germany 35385
Notes ongoing, but not recruiting participants - estimated completion May 2015
NCT01672216  (Continued)
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   EMG biofeedback versus balloon sensory biofeedback
Outcome or subgroup title No. of
studies
No. of partici-
pants
Statistical method Effect size
1 Number improved 2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
 
 
Analysis 1.1.   Comparison 1 EMG biofeedback versus balloon sensory biofeedback, Outcome 1 Number improved.
Study or subgroup EMG biofeed-
back
Balloon sen-
sory training
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Bleijenberg 1994 8/11 2/9 0% 3.27[0.91,11.71]
Koutsomanis 1995 18/29 16/30 0% 1.16[0.75,1.81]
Favours sensory training 100.1 50.2 20.5 1 Favours EMG
 
 
Comparison 2.   EMG biofeedback versus manometry biofeedback
Outcome or subgroup title No. of
studies
No. of partici-
pants
Statistical method Effect size
1 Number improved 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Analysis 2.1.   Comparison 2 EMG biofeedback versus manometry biofeedback, Outcome 1 Number improved.
Study or subgroup EMG biofeed-
back
Manometry
biofeedback
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Glia 1997 8/10 6/10 0% 1.33[0.74,2.41]
Favours manometry 100.1 50.2 20.5 1 Favours EMG
 
 
Comparison 3.   One method of biofeedback versus surgery
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Number improved 2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Constipation score 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
 
 
Analysis 3.1.   Comparison 3 One method of biofeedback versus surgery, Outcome 1 Number improved.
Study or subgroup Biofeedback Surgery Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Faried 2010 6/20 14/20 0% 0.43[0.21,0.89]
You 2001 35/40 17/20 0% 1.03[0.83,1.28]
Favours surgery 100.1 50.2 20.5 1 Favours biofeedback
 
 
Analysis 3.2.   Comparison 3 One method of biofeedback versus surgery, Outcome 2 Constipation score.
Study or subgroup Biofeedback Surgery Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Faried 2010 20 16.1 (1.5) 20 10.5 (1.5) 0% 5.6[4.67,6.53]
Favours biofeedback 105-10 -5 0 Favours surgery
 
 
Comparison 4.   One method of biofeedback versus Botulinum toxin-A
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Number improved 3   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Constipation score 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
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Analysis 4.1.   Comparison 4 One method of biofeedback versus Botulinum toxin-A, Outcome 1 Number improved.
Study or subgroup Biofeedback Botulinum
toxin-A
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Farid 2009 6/24 8/24 0% 0.75[0.31,1.83]
Faried 2010 6/20 7/20 0% 0.86[0.35,2.1]
You 2001 35/40 20/20 0% 0.89[0.77,1.02]
Favours botulinum toxin-A 100.1 50.2 20.5 1 Favours biofeedback
 
 
Analysis 4.2.   Comparison 4 One method of biofeedback versus Botulinum toxin-A, Outcome 2 Constipation score.
Study or subgroup Biofeedback Botulinum toxin-A Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Faried 2010 20 16.1 (1.5) 20 14.3 (1.5) 0% 1.8[0.87,2.73]
Favours biofeedback 105-10 -5 0 Favours botulinum toxin-A
 
 
Comparison 5.   EMG biofeedback versus electrical stimulation
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Bowel satisfaction score 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
 
 
Analysis 5.1.   Comparison 5 EMG biofeedback versus electrical stimulation, Outcome 1 Bowel satisfaction score.
Study or subgroup Biofeedback Electrical
stimulation
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Chang 2003 10 59 (28.8) 12 48.3 (34.1) 0% 10.7[-15.58,36.98]
Favours stimulation 5025-50 -25 0 Favours biofeedback
 
 
Comparison 6.   EMG biofeedback versus diazepam
Outcome or subgroup title No. of
studies
No. of partici-
pants
Statistical method Effect size
1 Number improved 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Analysis 6.1.   Comparison 6 EMG biofeedback versus diazepam, Outcome 1 Number improved.
Study or subgroup Biofeedback Diazepam Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heymen 2007 21/30 7/30 0% 3[1.51,5.98]
Favours diazepam 100.1 50.2 20.5 1 Favours biofeedback
 
 
Comparison 7.   EMG biofeedback versus STARR procedure
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Successful treatment 1   Risk Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Obstructed defecation score 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
 
 
Analysis 7.1.   Comparison 7 EMG biofeedback versus STARR procedure, Outcome 1 Successful treatment.
Study or subgroup Biofeedback STARR Risk Ratio Risk Ratio
  n/N n/N M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Lehur 2008 13/39 44/54 0.41[0.26,0.65]
Favours STARR 1000.01 100.1 1 Favours biofeedback
 
 
Analysis 7.2.   Comparison 7 EMG biofeedback versus STARR procedure, Outcome 2 Obstructed defecation score.
Study or subgroup Biofeedback STARR Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Lehur 2008 39 10.2 (5) 54 4.7 (5) 0% 5.5[3.44,7.56]
Favours biofeedback 105-10 -5 0 Favours STARR
 
 
Comparison 8.   One method of biofeedback versus control muscle relaxation
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Constipation severity index 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
2 IBS-QOL 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
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Analysis 8.1.   Comparison 8 One method of biofeedback versus
control muscle relaxation, Outcome 1 Constipation severity index.
Study or subgroup Biofeedback control mus-
cle relaxation
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Hart 2012 6 30 (14.1) 9 34.9 (7.6) 0% -4.9[-17.23,7.43]
Favours biofeedback 2010-20 -10 0 Favours control
 
 
Analysis 8.2.   Comparison 8 One method of biofeedback versus control muscle relaxation, Outcome 2 IBS-QOL.
Study or subgroup Biofeedback control mus-
cle relaxation
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Hart 2012 6 96.1 (42.1) 9 96.7 (27.4) 0% -0.6[-38.75,37.55]
Favours biofeedback 5025-50 -25 0 Favours control
 
 
Comparison 9.   EMG biofeedback versus laxative (movicol)
Outcome or subgroup title No. of
studies
No. of par-
ticipants
Statistical method Effect size
1 Major clinical improvement 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
 
 
Analysis 9.1.   Comparison 9 EMG biofeedback versus laxative (movicol), Outcome 1 Major clinical improvement.
Study or subgroup Biofeedback Laxative Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Chiarioni 2006 43/54 12/55 0% 3.65[2.17,6.13]
Favours laxative 100.1 50.2 20.5 1 Favours biofeedback
 
 
Comparison 10.   Manometry biofeedback versus sham
Outcome or subgroup ti-
tle
No. of
studies
No. of partici-
pants
Statistical method Effect size
1 CSBM 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
 
 
Analysis 10.1.   Comparison 10 Manometry biofeedback versus sham, Outcome 1 CSBM.
Study or subgroup Biofeedback Sham Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Rao 2007 24 4.6 (1) 28 2.8 (1.1) 0% 1.8[1.25,2.35]
Favours sham 105-10 -5 0 Favours biofeedback
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Comparison 11.   Manometry biofeedback versus standard care
Outcome or subgroup ti-
tle
No. of
studies
No. of partici-
pants
Statistical method Effect size
1 CSBM 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
 
 
Analysis 11.1.   Comparison 11 Manometry biofeedback versus standard care, Outcome 1 CSBM.
Study or subgroup Biofeedback Standard care Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Fixed, 95% CI   Fixed, 95% CI
Rao 2007 24 4.6 (1) 25 1.9 (1.5) 0% 2.7[1.99,3.41]
Favours standard care 105-10 -5 0 Favours biofeedback
 
 
A P P E N D I C E S
Appendix 1. Search strategies
The search strategies used for each database are outlined below.
The Cochrane Central Register of Controlled Trials (CENTRAL)
biofeedback AND constipation
The Cochrane Complementary Medicine Field
biofeedback AND constipation
The Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group Specialized Register
biofeedback AND constipation
MEDLINE
1. exp Constipation/
2. constipation.mp.
3. pelvic floor dyssynergia.mp.
4. exp Pelvic Floor/ or exp Defecation/ or exp Biofeedback, Psychology/ or exp Rectal Diseases/
5. anismus.mp.
6. exp Anus Diseases/ or exp Anal Canal/
7. 1 or 2 or 3 or 4 or 5 or 6
8. exp Biofeedback, Psychology/
9. biofeedback.mp.
10. 8 or 9
11. 7 and 10
12. limit 11 to yr="1966 -Current"
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13. limit 12 to yr="1980 -Current"
14. randomized controlled trial.pt.
15. randomized clinical trial.pt.
16. randomised.ab.
17. placebo.ab.
18. randomly.ab.
19. trial.ab.
20. groups.ab.
21. 14 or 15 or 16 or 17 or 18 or 19 or 20
22. limit 21 to humans
23. 13 and 22
24. limit 23 to "all adult (19 plus years)"
CINAHL
(MH "Constipation") AND (MH "Biofeedback")
British Nursing Index (BNI)
1. exp Constipation/
2. constipation.mp. [mp=title, abstract, heading words]
3. pelvic floor dyssynergia.mp. [mp=title, abstract, heading words]
4. anismus.mp. [mp=title, abstract, heading words]
5. 1 or 2 or 3 or 4
6. biofeedback.mp. [mp=title, abstract, heading words]
7. 5 and 6
8. limit 7 to yr="1980 -Current"
9. randomized controlled trial.mp. [mp=title, abstract, heading words]
10. randomized.mp. [mp=title, abstract, heading words]
11. placebo.mp. [mp=title, abstract, heading words]
12. randomly.mp. [mp=title, abstract, heading words]
13. trial.mp. [mp=title, abstract, heading words]
14. 9 or 10 or 11 or 12 or 13
15. 8 and 14
EMBASE
1. exp feedback system/
2. biofeedback.mp.
3. 1 or 2
4. exp constipation/
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5. constipation.mp.
6. pelvic floor dyssynergia.mp.
7. anismus.mp.
8. 4 or 5 or 6 or 7
9. 3 and 8
10. limit 9 to yr="1980 -Current"
11. limit 10 to human
12. limit 11 to (adult <18 to 64 years> or aged <65+ years>)
13. random$.mp.
14. factorial$.mp.
15. crossover$.mp.
16. cross over$.mp.
17. cross-over$.mp.
18. placebo$.mp.
19. (doubl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
20. (singl$ adj blind$).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug
manufacturer name]
21. assign$.mp.
22. volunteer$.mp.
23. 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22
24. crossover procedure/
25. double blind procedure/
26. randomized controlled trial/
27. single blind procedure/
28. allocat$.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufac-
turer name]
29. 23 or 24 or 25 or 26 or 27 or 28
30. 12 and 29
PsychINFO
1. exp Constipation/
2. constipation.mp. [mp=title, abstract, heading word, table of contents, key concepts]
3. pelvic floor dyssynergia.mp. [mp=title, abstract, heading word, table of contents, key concepts]
4. anismus.mp. [mp=title, abstract, heading word, table of contents, key concepts]
5. 1 or 2 or 3 or 4
6. exp Biofeedback/
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7. exp Biofeedback Training/
8. biofeedback.mp. [mp=title, abstract, heading word, table of contents, key concepts]
9. 6 or 7 or 8
10. 5 and 9
11. limit 10 to yr="1980 -Current"
12. limit 11 to human
13. limit 12 to "300 adulthood "
14. limit 13 to ("0400 empirical study" or "0430 followup study" or "0450 longitudinal study" or "0451 prospective study" or "0452 retro-
spective study" or 1800 quantitative study or "2000 treatment outcome/randomized clinical trial")
SCOPUS
TITLE-ABS-KEY(constipation OR "pelvic floor dyssynergia" OR anismus) AND TITLE-ABS-KEY(biofeedback) AND PUBYEAR AFT 1979 AND
("randomized controlled trial")
Science Citation Index Expanded (SCI-EXPANDED)
biofeedback AND constipation
Social Sciences Citation Index (SSCI)
biofeedback AND constipation
Conference Proceedings Citation Index - Social Science and Humanities (CPCI-SSH)
biofeedback AND constipation
Conference Proceedings Citation Index - Science (CPCI-S)
biofeedback AND constipation
F E E D B A C K
Letter to editor from Rao et al
Summary
The Editor
The Cochrane Collaboration Editorial Unit
Attn: Hilary Simmonds
Dear Sir/Madam:
Re: Woodward S, Norton C, Chiarelli P. Biofeedback for treatment of chronic idiopathic constipation in adults. Cochrane Database Syst
Rev 2014; Issue 3: CD008486.
We are an international group comprising physiologists, biofeedback therapists, research investigators, gastroenterologists, and colorec-
tal surgeons with a strong interest and published record of original scientific work in the field of dyssynergic defecation and constipation.
We have always appreciated the thorough and meticulous work of the “Cochrane Review” process. However, we believe that this review,
although timely, is flawed and is potentially a disservice to the community of health care providers who manage these patients. The authors
have made unsupported and arguably incorrect assumptions in their review of the published studies , and at time have misquoted the
studies or the interpretation of data. Based on this flawed evidence, the authors conclude that the studies are of low quality or carry
significant risk of bias and that there is insufficient evidence to recommend biofeedback treatment.
The randomized controlled trials (RCTs) published in the past 7 years have employed rigorous selection criteria, appropriate diagnosis
and well-defined outcome measures, and they included 370 patients1-3. These key RCT studies came from several major centers across
the world and all groups working independently have concluded that biofeedback therapy is efficacious and superior to appropriate com-
parison groups. In contrast to the recommendations of this review, we believe that the evidence is compelling that biofeedback thera-
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py is efficacious both in the short-term and long-term management of disordered defecation. Major professional societies including the
American College of Gastroenterology4, the American Gastroenterological Association5,, and the Rome Foundation6 have reached similar
conclusions.
Our concerns with the methods used by the reviewers are as follows:
Heterogeneous groups: In a number of cited studies, the authors have included patients with diverse conditions, many of whom have
no clear rationale for biofeedback therapy. These include patients with isolated slow transit constipation, rectoceles, outlet obstruction,
rectal mucosal intussusception, and rectal prolapse.
Inclusion of early pilot studies: The inclusion of studies performed decades ago is problematic, as the methodology and analyses were
rudimentary, patient selection criteria were unclear and randomization was not performed. The deficiencies of these early studies should
not negatively color the description of more recent rigorous studies and should have been excluded.
Estimating Risk of Bias – This is a very useful method if applied correctly. We believe that the authors have in some instances incorrectly
interpreted the data and consequently arrived at erroneous conclusions. For example, the study by Rao et. al.1 was a rigorously performed
clinical trial that was sponsored by the NIH and to date, is the only sham controlled treatment trial of biofeedback. The study was consid-
ered to be a “high risk for bias” and the authors assumed the power calculations were not performed; this was puzzling, as this was an
NIH sponsored clinical trial. Indeed, detailed sample size
Calculations formed the basis for the award of the grant. A consort diagram was provided in the manuscript giving a clear disposition of
all subjects enrolled and screened, yet the review states that such was not provided. This was also true for the study by Heymen et al3 and
Chiarioni et al2 , which were also described as “high risk of bias”; the target enrollment was specified and information was also published
on clinical trials.gov. Finally, it was incorrectly stated by the authors that there was bias in subject selection in the Rao study. Subjects
were randomly allocated to one of 3 treatments using a permuted blocks method using sealed envelopes and concealed allocation. When
the data were compared, there was no difference among the three groups, with regards to demographics, non-compliance rates, number
of therapy sessions, baseline bowel symptoms and in 8 of 12 manometric features. There were minor out significant differences in only 3
manometric features at baseline and these minor differences alone should not constitute grounds for a high risk of bias. Furthermore, the
stated main concern was that patients who received biofeedback treatment had more severe symptoms. If so, one could hypothesize that
they should have fared worse, but in fact they showed significant improvement in outcomes.
Contacting authors for missing data and clarification: The guidelines for conducting Cochrane reviews include an obligation to contact
the authors of studies when important information is missing or unclear. The authors state that they did this. However, authors Rao1,
Chiarioni2, and Heymen3 and their research teams were not contacted. If this had been done, it is likely that the reviewers would have
drawn different conclusions regarding the risk of bias.
Blinding: The reviewers insist that the masking of active vs. control interventions from both the investigator and the patient, which is a
feasible standard for study design in drug trials, should be applied to behavioral therapies such as biofeedback. However, it is not possible
to double-blind a behavioral therapy trial, and alternative criteria have been recommended for managing this source of bias in behavioral
trials7. These guidelines include choosing a comparison treatment that is credible to patients, randomizing patients only after eligibility
has been confirmed, assessing the expectation of benefit b questionnaire in both the active and control arms of the study after initial
exposure to the assigned treatment, and using independent blinded assessors to collect outcome data. These techniques were employed
in several of the recent RCTs, but this is not mentioned by the reviewers.
Inclusion of older abstracts: While it seems reasonable to include recent abstracts whose findings have significant implication for treat-
ment, patient management, outcome or safety, it seems inappropriate to include abstracts published in 2006 and 2007, none of which
have been published in a peer reviewed manuscript and therefore are unavailable to clinicians and researchers in the Cochrane review.
Surgical Therapies & STARR Procedures: Rectal mucosal intussusception, excessive Pelvic floor descent, rectoceles etc, are not the same
conditions as dyssynergic defecation should be omitted from this review.
Reporting of adverse-events: The authors state that firm conclusions cannot be made regarding potential side-effects of biofeedback
treatment, but not a single trial has ever reported an adverse event and biofeedback is generally described as safe. To posit that this
treatment may be unsafe suggests an overall negative bias by the authors.
In summary, there are serious methodological flaws with this systematic review. The conclusions are inaccurate. Contrary to the statement
in the review, the signatories to this letter many of whom have authored some of the studies cited in the review were not contacted by the
authors of the Cochrane review. Because of the many aforementioned reasons, this review should be retracted. A re-assessment would
be appropriate, either by the original authors or by an independent external set of reviewers
Many thanks for considering our request. Please allow us to reiterate our firm support and confidence in the Cochrane Review process.
Sincerely,
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Reply
Author and IBD/FBD group response to letter from Rao et al
Our review was clear in its scope: chronic idiopathic constipation of whatever origin. This is the condition for which biofeedback has been
trialled and used in clinical practice in most of the world. We did not set out to do a more restricted review of biofeedback for obstructed or
dyssynergic defecation and pre-specified subgroup analyses on patient subgroups was not possible due to an insufficient number of stud-
ies. We could consider doing this sub-group analysis in future updates, but as many studies have not reported these patients separately,
this would inevitably be selective to mostly the USA studies. The comments take a very USA-focused approach, where clinical practice
has evolved in some clinics, including those of the signatories, to include only patients who meet the arbitrary definition of “dyssynergic
defecation”. This is not the clinical or research practice in most of the rest of the world.
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Some of the signatories have a vested interest in the outcome of this review as they have large private practice biofeedback clinics and large
grants investigating biofeedback therapy. They are noted to be the authors of the studies they are defending (Heymen, Rao, Chiarioni).
The protocol for the review was published in 2010 in the Cochrane library (Issue 4. Art. No.: CD008486. DOI: 10.1002/14651858.CD008486),
giving the signatories ample opportunity to comment on the methods prior to the publication of the review and yet none were received.
We address each of the points from the letter below (see italic text ).
---------------------------------------------------------
The Editor
The Cochrane Collaboration Editorial Unit
Attn: Hilary Simmonds
Dear Sir/Madam:
Re: Woodward S, Norton C, Chiarelli P. Biofeedback for treatment of chronic idiopathic constipation in adults. Cochrane Database Syst
Rev 2014; Issue 3: CD008486.
We are an international group comprising physiologists, biofeedback therapists, research investigators, gastroenterologists, and colorec-
tal surgeons with a strong interest and published record of original scientific work in the field of dyssynergic defecation and constipation.
We have always appreciated the thorough and meticulous work of the “Cochrane Review” process. However, we believe that this review,
although timely, is flawed and is potentially a disservice to the community of health care providers who manage these patients. The authors
have made unsupported and arguably incorrect assumptions in their review of the published studies, and at time have misquoted the
studies or the interpretation of data. Based on this flawed evidence, the authors conclude that the studies are of low quality or carry
significant risk of bias and that there is insufficient evidence to recommend biofeedback treatment.
Response: We did not conclude that there was insufficient evidence to recommend biofeedback treatment. In the implications for treatment
section we provided a general interpretation of the evidence so that it can inform healthcare or policy decisions. Our conclusion was, “Currently
there is insufficient evidence to allow any firm conclusions regarding the efficacy and safety of biofeedback for the management of people
with chronic constipation. We found low or very low quality evidence from single studies to support the effectiveness of biofeedback for the
management of people with chronic constipation and dyssynergic defecation. However, the majority of trials are of poor methodological
quality and subject to bias. Further well-designed randomised controlled trials with adequate sample sizes, validated outcome measures
(especially patient reported outcome measures) and long-term follow-up are required to allow definitive conclusions to be drawn.”
The randomized controlled trials (RCTs) published in the past 7 years have employed rigorous selection criteria, appropriate diagnosis
and well-defined outcome measures, and they included 370 patients1-3. These key RCT studies came from several major centers across
the world and all groups working independently have concluded that biofeedback therapy is efficacious and superior to appropriate com-
parison groups. In contrast to the recommendations of this review, we believe that the evidence is compelling that biofeedback thera-
py is efficacious both in the short-term and long-term management of disordered defecation. Major professional societies including the
American College of Gastroenterology4, the American Gastroenterological Association5,, and the Rome Foundation6 have reached similar
conclusions.
Response: The letter implies that they want a review with only their three studies included. It is against all the principles of Cochrane to select
studies in this way. All of the studies that were included in the review including the three cited studies met our pre-specified inclusion criteria
that were published in the protocol for the review.
Our concerns with the methods used by the reviewers are as follows:
Heterogeneous groups: In a number of cited studies, the authors have included patients with diverse conditions, many of whom have
no clear rationale for biofeedback therapy. These include patients with isolated slow transit constipation, rectoceles, outlet obstruction,
rectal mucosal intussusception, and rectal prolapse.
Response: All of the studies included in our review met our pre-defined inclusion criteria. It is the authors of the included biofeedback studies,
not the review authors, who included heterogeneous patient groups. This we believe reflects clinical practice around the world. It should be
noted that meta-analysis was not possible due to differences between study populations, the heterogeneity of the different samplesand
the large range of different outcome measures utilized in the included studies. If a sufficient number of randomised trials were identified, we
planned a subgroup analysis by constipation sub-type. However there wasn't a sufficient number of studies to allow such an analysis. This
could be considered for future updates of the review.
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Inclusion of early pilot studies: The inclusion of studies performed decades ago is problematic, as the methodology and analyses were
rudimentary, patient selection criteria were unclear and randomization was not performed. The deficiencies of these early studies should
not negatively color the description of more recent rigorous studies and should have been excluded.
Response: All of the studies included in the review met the pre-defined inclusion criteria which were randomised controlled trials comparing
one method of biofeedback for constipation with sham treatment, conventional treatment, no treatment or another method of biofeedback
in patients with constipation were considered for inclusion. Arbitrary exclusion by publication date is not warranted. We followed Cochrane
methods and searched systematically for all studies reported since the first case series report of biofeedback for this indication in 1980. We
were deliberately non-selective as this was the first Cochrane review on the subject. We did not include any non-randomised studies. It is
notable that some more recent studies also have rudimentary reporting and methods and the limitations of the included studies are clearly
described in the review and taken into consideration when drawing conclusions.
Estimating Risk of Bias – This is a very useful method if applied correctly. We believe that the authors have in some instances incorrectly
interpreted the data and consequently arrived at erroneous conclusions. For example, the study by Rao et. al.1 was a rigorously performed
clinical trial that was sponsored by the NIH and to date, is the only sham controlled treatment trial of biofeedback. The study was consid-
ered to be a “high risk for bias” and the authors assumed the power calculations were not performed; this was puzzling, as this was an
NIH sponsored clinical trial. Indeed, detailed sample size
Calculations formed the basis for the award of the grant. A consort diagram was provided in the manuscript giving a clear disposition of
all subjects enrolled and screened, yet the review states that such was not provided. This was also true for the study by Heymen et al3 and
Chiarioni et al2 , which were also described as “high risk of bias”; the target enrollment was specified and information was also published
on clinical trials.gov. Finally, it was incorrectly stated by the authors that there was bias in subject selection in the Rao study. Subjects
were randomly allocated to one of 3 treatments using a permuted blocks method using sealed envelopes and concealed allocation. When
the data were compared, there was no difference among the three groups, with regards to demographics, non-compliance rates, number
of therapy sessions, baseline bowel symptoms and in 8 of 12 manometric features. There were minor out significant differences in only 3
manometric features at baseline and these minor differences alone should not constitute grounds for a high risk of bias. Furthermore, the
stated main concern was that patients who received biofeedback treatment had more severe symptoms. If so, one could hypothesize that
they should have fared worse, but in fact they showed significant improvement in outcomes.
Response: We believe that our risk of bias assessment is correct.
Rao 2007 was rated as high risk of bias for ‘blinding’ and ‘other bias’. The study was assessed as high risk for blinding for two reasons. This
was a three arm trial that included a biofeedback group, a sham biofeedback group and a standard care group. It would be obvious to the
patients in the groups that they were receiving biofeedback or standard care. We also had doubts about blinding for patients in the sham
biofeedback group. In fact Rao et al state on page p332 of their manuscript, “Although the therapist and patient could not be blinded, the
manometry reader was unaware of patient assignment or previous data.” They did not report assessing the success of blinding and there is
no report that they intended to assess this outcome. This statement in the paper by the authors themselves strongly suggests that patients
were not blinded between the different interventions and that is why we came to the conclusion that the risk of bias for blinding was high.
The Rao 2007 study was judged to be at high risk of bias for ‘other bias’ because of baseline differences between the biofeedback and sham
groups in the defecation index and pelvic floor dysfunction. Other possible sources of bias in the Rao 2007 study were discussed in the review
but did not inform our risk of bias assessment.
Heyman 2007 was rated as high risk of bias for ‘blinding’ and ‘other bias’. The study was assessed as high risk of for blinding because both
investigators and patients knew whether the patients were assigned to biofeedback or diazepam. The study was rated a high risk of ‘other
bias’ due to possible self-selection bias.
Chiarioni 2206 was rated as high risk of bias for ‘blinding’ because both investigators and patients knew whether the patients were assigned
to biofeedback or laxatives.
Other issues with these three studies are detailed below.
Heymen (2007) compared biofeedback with diazepam and an inert placebo. The lead investigator/therapist telephoned the participants
three months after treatment and asked if they “obtained adequate relief”. This outcome measure is open to bias as the participants had by
this time spent 6 x 30 minute sessions with the investigator. Futher this outcome does not appear to have been validated. The study included
patients with slow transit constipation which the signatories suggest should have been excluded. Diazepam was used as a comparator with
no previous published evidence for efficacy. The authors cite their own clinical practice as a justification. We have not been able to find any
other studies using this intervention. Diazepam clearly did not work as hypothesised (see their Figure 4 p 437) as dyssynergia worsened rather
than improved in these patients, and there was a high drop-out rate which the authors attribute to side effects. There is no empirical evidence
that we are aware of that diazepam relaxes the pelvic floor. The authors report multiple secondary outcomes, mostly with non-significant dif-
ferences. Recruitment was stopped early before reaching target recruitment numbers because an interim analysis indicated that 30 patients
per group showed a significant difference for the primary outcome between biofeedback and the two pill groups. This is a pity because final
completions were only 66 of the 90 needed rendering the study underpowered. The authors have erroneously summed the SF36 scores rather
than reporting subscales. The authors conclusions that “instrumented biofeedback is essential to successful treatment” seems over-stated as
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there was only a trend in favour of biofeedback compared with diazepam (p=0.067) in number of unassisted bowel movements as highlighted
in the abstract as a major outcome. Perhaps if the study had continued to full recruitment it would have yielded more definitive results. The
authors state that follow up data collection is continuing, but we have found no published follow up results.
Chiarioni (2006) was on the whole a well conducted study. It did include slow transit constipation which the signatories felt should be excluded
(we disagree). There is a sample size calculation, albeit on the un-supported presumption that 25% difference between groups would be
clinically meaningful. However, to highlight in results that biofeedback group had a significantly greater reduction in laxative use than the
comparison group whose intervention was laxatives seems a little biased in favour of biofeedback. To claim repeatedly in the paper that this
is a “large” study with just over 100 patients seems a little exaggerated.
Rao (2007) report (and do not adequately explain) selective recruitment. Three hundred of 377 screened patients were excluded: 148 did not
meet inclusion criteria (unstated which) and 152 refused. Seventy-seven patients were recruited. There was no a priori sample size justification
in the paper nor on any of the updates published on the Clinicaltrials.gov website so it is unclear if target recruitment was met.
The long term follow up of the same study (Rao 2010) is reported largely as if it was a new study (citing “our earlier study” as if it were a different
one), with only 2 of the 3 original randomized groups even mentioned (they have omitted to mention the sham group at all in the text and
in the CONSORT diagram) and changing the primary outcome measure from the two primary outcomes in the primary study reference to a
single primary outcome “complete spontaneous bowel motions” (CSBM), dropping satisfaction, in the manuscript reporting long term follow
up results. There is no mention of power in either manuscript nor on the clinicaltrials.gov website. Of 77 patients originally randomized to
three groups (or 52 to 2 groups as reported in the manuscript reporting follow up results) only 7/24 completed the laxative arm and 13/28 the
biofeedback arm at 12 months (20/52, 38%, in the 2 arms). There is also no statistical comparison presented between the groups at one year,
only a within group comparison, in groups which were not well matched at baseline. One of the primary outcomes (satisfaction) in the primary
study reference was not significantly different between the groups in the follow up manuscript. It seems that this was selectively dropped
as a primary outcome to give a positive report on biofeedback. The ROME group are keen to promote patient based outcome measures in
functional bowel disorders. This author seems to be going against this and selecting the arbitrary CSBM as having primacy.
The concept of CSBM (i.e. laxative free defecation) when one of the intervention arms was a laxative intervention, inevitably makes biofeedback
look better: the comparison group were instructed to take laxatives and then counted as worse if they did so. Rao et al selected a “sham” that
would in some clinical practices be considered active biofeedback. Use of a manometry probe with progressive muscle relaxation and balloon
distensions to “promote awareness for stooling and match sensory conditioning provided under biofeedback” is a comparator biofeedback
protocol, not a placebo in our opinion. The more severe symptoms at baseline gave greater capacity to benefit in the biofeedback group. We
have not been able to find the abstract quoted in the 2010 paper (Am J Gastro 2005), but did find one in Gastroenterology of the same study.
Contacting authors for missing data and clarification: The guidelines for conducting Cochrane reviews include an obligation to contact
the authors of studies when important information is missing or unclear. The authors state that they did this. However, authors Rao1,
Chiarioni2, and Heymen3 and their research teams were not contacted. If this had been done, it is likely that the reviewers would have
drawn different conclusions regarding the risk of bias.
Response: We contacted authors for additional information when we felt the available information was unclear or missing. We attempted
to contact Farid/Faried, but received no reply. We also contacted Dr Peyman Adibi regarding the Pourmomeni 2010 study and received a
response confirming duplicate publication of a single study. We did not feel it was necessary to contact the authors of Heyman 2007 for further
information. Two of the cited studies (Rao and Heymen) had further information available on clinicaltrails.gov and we took this as definitive
information and we did not need to contact the authors for further information.
Blinding: The reviewers insist that the masking of active vs. control interventions from both the investigator and the patient, which is a
feasible standard for study design in drug trials, should be applied to behavioral therapies such as biofeedback. However, it is not possible
to double-blind a behavioral therapy trial, and alternative criteria have been recommended for managing this source of bias in behavioral
trials7. These guidelines include choosing a comparison treatment that is credible to patients, randomizing patients only after eligibility
has been confirmed, assessing the expectation of benefit b questionnaire in both the active and control arms of the study after initial
exposure to the assigned treatment, and using independent blinded assessors to collect outcome data. These techniques were employed
in several of the recent RCTs, but this is not mentioned by the reviewers.
Response: We have nowhere insisted that blinding can or should be done in trials assessing behavioral interventions. However, blinding can
be achieved by the use of an appropriate sham and it is possible to blind outcome assessors. We have simply reported on how blinding was
utilized in the included studies for the risk of bias assessment. We clearly stated that “it is acknowledged that it is difficult to blind either
participants or therapists in behavioural studies, however outcome assessors could have remained blind to treatment allocation.”
Inclusion of older abstracts: While it seems reasonable to include recent abstracts whose findings have significant implication for treat-
ment, patient management, outcome or safety, it seems inappropriate to include abstracts published in 2006 and 2007, none of which
have been published in a peer reviewed manuscript and therefore are unavailable to clinicians and researchers in the Cochrane review.
Response: We did not pre-specify the exclusion of abstract publications in our protocol. Two abstract publications were included in the review
(Hu 2006 and Jung 2007) and these studies are clearly described as abstracts in the text and characteristics of included studies table.
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Surgical Therapies & STARR Procedures: Rectal mucosal intussusception, excessive Pelvic floor descent, rectoceles etc, are not the same
conditions as dyssynergic defecation should be omitted from this review.
Response: The focus of our review focus was on biofeedback for the treatment of chronic constipation not necessarily constipation due to
dyssynergic defecation. We included all RCTs that compared biofeedback to sham treatment, conventional treatment, no treatment or another
method of biofeedback without selecting what we consider to be appropriate interventions or not. We utilized a pretty liberal interpretation of
what constituted ‘conventional treatment’. For example, we might as easily have decided that diazepam was not as appropriate as surgical
procedures which are indeed used in clinical practice. We clearly stated our concerns about some of the surgical studies and highlighted the
high complication rates that occurred in the surgery groups in the review.
Reporting of adverse-events: The authors state that firm conclusions cannot be made regarding potential side-effects of biofeedback
treatment, but not a single trial has ever reported an adverse event and biofeedback is generally described as safe. To posit that this
treatment may be unsafe suggests an overall negative bias by the authors.
Response: We concluded that there was insufficient evidence to draw any firm conclusions on safety because of the paucity of data on safety
outcomes. In the abstract and plain language summary we clearly state “No adverse events were reported for biofeedback, although this was
not specifically reported in the majority of studies.” This point is reiterated in the ‘Implications for Practice’ section of the ‘Authors’ conclusions’
where we state “There were no reports of adverse events from biofeedback in any of the studies and it is fairly unlikely that this intervention
will cause significant harm.” At no point did we make any suggestion that biofeedback is unsafe.
In summary, there are serious methodological flaws with this systematic review. The conclusions are inaccurate. Contrary to the statement
in the review, the signatories to this letter many of whom have authored some of the studies cited in the review were not contacted by the
authors of the Cochrane review. Because of the many aforementioned reasons, this review should be retracted. A re-assessment would
be appropriate, either by the original authors or by an independent external set of reviewers
Response: We disagree – this review was subject to substantial editorial and peer review. We contacted authors as necessary but would be
delighted to have additional information from the signatories if this is available. We strongly believe that this review provides a balanced
assessment of the current state of knowledge regarding the use of biofeedback for the treatment of chronic constipation.
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C O N T R I B U T I O N S   O F   A U T H O R S
Two review authors (S. Woodward and C. Norton) wrote the initial review protocol. The same two review authors (SW and CN) examined
all citations and abstracts derived from the electronic searches and independently screened the trial reports to identify those that met the
selection criteria for the review. Both SW and CN reviewed the methodological quality of the included studies. All three authors interpreted
the results and contributed to the writing of the final version of the review.
D E C L A R A T I O N S   O F   I N T E R E S T
Sue Woodward: SW and CN have designed and recently completed an unfunded RCT comparing biofeedback with reflexology for consti-
pation (being prepared for publication).
Christine Norton: CN has been paid an honorarium by Genesis Lt (UK), who market biofeedback equipment, for speaking at an educational
event. CN is partly employed by St Mark’s Hospital, Harrow UK, which provides treatment, including biofeedback, for patients with con-
stipation.
Pauline Chiarelli: PC was part of a team of 15 Australian experts from various healthcare professions who developed the recently published
'Guidelines for the management of constipation and faecal impaction in older adults'. The development of these guidelines was instigated
by Norgine Pty Ltd under the auspices of the Continence Foundation of Australia. PC was paid an honorarium for this work.
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Medical Subject Headings (MeSH)
Botulinum Toxins, Type A   [therapeutic use];   Chronic Disease;   Constipation   [*therapy];   Diazepam   [therapeutic use];   Feedback,
Physiological   [*physiology];   Laxatives   [therapeutic use];   Muscle Relaxants, Central   [therapeutic use];   Neurofeedback   [methods];
  Neuromuscular Agents  [therapeutic use];  Randomized Controlled Trials as Topic
MeSH check words
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